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ABSTRACT
REGULATION OF P-GLYCOPROTEIN AND ABCP
TRANSPORTERS
Dhanashri R. Kolwankar
The placenta plays an important role in modulating xenobiotic passage from
mother to fetus. Smoking is known to induce cytochrome P450 1A1 (CYP1A1)
expression in the placenta, however its effect on P-glycoprotein (P-gp) and ABC
transporter in placenta (ABCP) levels in placenta is not known. In-vitro studies in
hepatocytes have reported induction of P-gp mRNA by some polycyclic aromatic
hydrocarbons. To examine whether smoking can affect placental P-gp and ABCP, their
expression and activity were determined in placentas from smokers and non-smokers.
Uptake of [3H]-vinblastine and [3H]-mitoxantrone was used to measure P-gp and ABCP
function, respectively and CYP1A1 activity (positive control) was assessed using
ethoxyresorufin O-deethylation as the model reaction. P-gp and ABCP expression was
measured by immunoblotting. Uptake of [3H]-vinblastine in vesicles was osmotically
sensitive, suggesting intravesicular accumulation and was inhibited by verapamil, a P-gp
inhibitor. Uptake of [3H]-mitoxantrone was inhibited by fumitremorgin C, an ABCP
inhibitor but not by verapamil. Though CYP1A1 activity was significantly higher in
smokers, no statistical difference (P > 0.05) was noted in P-gp and ABCP function or
expression between smokers and non-smokers suggesting that smoking has no effect on
placental P-gp and ABCP activity or expression.
In order to study the induction of P-gp, we used LS174T cells to screen for
compounds for their ability to induce P-gp. As CYP3A4 and P-gp are coordinately
upregulated, CYP3A activity was also assessed as the formation of 1’-hydroxy
midazolam. Uptake of VBL was used to measure P-gp function and expression was
measured by immunochemical methods. CYP3A activity was 4 times higher and P-gp
activity was significantly higher after rifampin treatment. Rifampin treatment also
produced an increase in protein abundance and surface expression of P-gp. To assess
involvement of the Pregnane X Receptor (PXR) in P-gp induction, a set of multiple
compounds with varying degrees of PXR activation were evaluated for effect on P-gp
expression. PXR activation and P-gp expression were positively correlated, supporting
the role of PXR in regulation of P-gp. These data suggest that LS174T cells have the
potential to be used in studying the effect of inducers on CYP3A and P-gp
simultaneously.
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CHAPTER – I
1. LITERATURE REVIEW

1

The placenta provides a link between mother and fetus, playing a critical
role in the provision of nutrition and growth factors that are necessary for the
development of the fetus. The placenta also plays a protective function by serving as
a barrier against many xenobiotics reaching the fetus. Generally, it is preferred that
the fetus not be exposed to xenobiotics; however, in certain cases the transfer of drugs
to the fetus may be desired to achieve a positive therapeutic outcome. The placenta
also possesses drug metabolizing enzymes (DME) that can assist in metabolizing
drugs ingested by the mother and thus are prevented from entering the fetus. In
addition to DMEs, it has also been demonstrated that efflux transporters are present in
the placenta that can transport xenobiotics back to the mother and prevent fetal
toxicity.

1.1. Efflux Transporters
The ATP- Binding Cassette (ABC) transporter superfamily represents the
ABC genes which encode for transmembrane proteins. These proteins utilize ATP as
the energy source to carry out efflux of xenobiotics and are termed as ABC
transporters. These ABC transporters have ATP binding domains and transmembrane
domains and depending on the number of domains, they are divided as full or half
transporters. So far, 48 ABC genes belonging to this ABC superfamily have been
identified and the Human Genome Nomenclature Committee has developed a
nomenclature system for the genes belonging to this superfamily. These genes have
been classified into seven subfamilies, ABCA – ABCG, based on their sequence
homology in ATP binding domains and transmembrane domains, similarities in gene
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structure and order of domains [1]. Table 1.1 lists the subfamilies and number of
genes belonging to each subfamily. The members within each subfamily are then
assigned an arabic number as a suffix. Out of the 48 transporters, 2 transporters
studied by us are discussed in this manuscript and are listed in Table 1.2. The
currently accepted nomenclature will be used throughout for consistency.
extensive

list

of

48

transporters

can

be

An

found

at

http://nutrigene.4t.com/humanabc.htm

Table 1-1 Division of ABC superfamily of transporters into seven subfamilies
Name

ABC1

MDR

MRP

ALD

OABP

GCN20

White

Subfamily

ABCA

ABCB

ABCC

ABCD

ABCE

ABCF

ABCG

Members

12

11

12

4

1

3

5

Table 1-2 New nomenclature for the ABC transporter proteins
Old nomenclature for the

New nomenclature for the

Protein encoded by the

gene

gene

gene

MDR1

ABCB1

BCRP / MXR/ABCP

ABCG2

P-gp
BCRP / MXR/ABCP

MRP

ABCC1-6

MRP 1-6

3

1.2. P-glycoprotein (P-gp)
P-gp is encoded by the ABCB1 gene which belongs to the adenosine 5’triphosphate (ATP) binding cassette superfamily of proteins known as ABC
transporters. The proteins belonging to this superfamily utilize ATP as the energy
source to carry out the active efflux of xenobiotics. P-gp is a 1280 amino acid
transmembrane protein with a molecular weight of 170 kDa. The ABCB1 gene has
been mapped to choromosome 7q21.1 [2;3]. Structurally, P-gp has a total of 12
transmembrane domains divided into homologous regions (Figure 1.1). Each half
contains 6 transmembrane domains and an intracellular ATP binding domain (also
known as a nucleotide binding domain) [4]. These transmembrane domains bind to
hydrophobic drugs and pump them out of cells. The development of resistance to
chemotherapeutic agents in some tumor cells is attributable to the active efflux of
these agents by P-gp. This efflux utilizes the energy from ATP hydrolysis. With the
help of stoichiometric studies it has been shown that two ATP molecules are
hydrolyzed for the transport of each substrate molecule [5;6]. However both these
events do not take place simultaneously, rather there are two independent ATP
hydrolysis events in a single catalytic cycle [7]. Hydrolysis of one ATP molecule
results in transport of the substrate whereas the other causes a conformational change
necessary to reset the efflux pump for the next catalytic cycle [7].
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A
N-terminal

C-terminal

ATP

ATP

B
N-terminal

C-terminal

ATP

Figure 1-1 Schematic representation of ABC efflux transporter structure
The structures of ABC efflux transporters: P-gp (A), encoded by ABCB1 gene, which has
12 transmembrane domains and two ATP binding sites and ABCP (B), encoded by
ABCG2 gene, which has 6 transmembrane domains and one ATP binding site. The Nterminal is the amino terminal and C-terminal is the carboxy terminal. Figure adapted
from Gottesman et al. [8].
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1.2.1. Tissue Distribution and Function of P-gp
P-gp is present not only in tumor cells but also in normal tissues [9] and
plays a very important role in the absorption, distribution and excretion of drugs. It is
expressed in the intestinal epithelium whereby it pumps drugs back into the gut
lumen, thus affecting absorption and decreasing oral bioavailability. Located at the
apical membranes of hepatocytes and proximal tubules of the kidney, P-gp transports
drugs into bile and urine, respectively, thus facilitating their biliary and urinary
elimination. The blood brain barrier (BBB) prevents a variety of xenobiotics from
entering the brain and helping prevent central nervous system (CNS) toxicity. P-gp is
located on the luminal surface of the capillary endothelium of the BBB and facilitates
efflux of xenobiotics back into the blood, thus reducing CNS exposure.
Animal models have been utilized to study the role of P-gp in the transport
of xenobiotics. Although humans express a single ABCB1 gene, there are two highly
homologous mdr1 genes in mice, termed mdr1a and mdr1b. Substantial overlap is
seen in substrate specificity and tissue distribution between the P-gp’s from mouse
and human and therefore these transporters are believed to play similar roles in these
species [10]. Due to these similarities, an mdr knockout (KO) mouse, created by a
targeted disruption of the mdr gene, has proven to be a very useful model to study the
contributions of P-gp in drug pharmacology. Kim et al. [11] in a study with KO mice
demonstrated that plasma levels of HIV protease inhibitors like indinavir, saquinavir
and nelfinavir, P-gp substrates, were 2 - 5 times higher in mdr1a KO mice as
compared to wild type (WT) mice. In addition, these investigators also found the
concentrations of these drugs to be 7-36 fold higher in the brains of KO mice after
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intravenous administration as compared to WT. A subpopulation of CF-1 mice that is
naturally deficient in mdr1a has also been used in similar studies to understand the
role of P-gp as these mice are phenotypically similar to the mdr KO mice. Kwei et al.
[12] used these mdr1a deficient mice to investigate the disposition of ivermectin and
cyclosporin A. Higher concentrations of ivermectin and cyclosporin A were seen in
the brain and blood of mdr1a deficient mice as compared to CF-1 WT mice after
intravenous or oral administration. These studies demonstrated that P-gp not only
governs the absorption and distribution of drugs but also plays a protective role by
preventing the transport of drugs across the BBB. In addition to being expressed at
the brain capillary endothelium, P-gp is also expressed in placenta. Lankas et al.
performed studies in the mdr1a deficient mice and its findings provided evidence for
the role of placental P-gp in protection of the developing fetus [13]. An isomer of the
pesticide avermectin, a substrate for P-gp, is known to produce cleft palate. The
pregnant dams were exposed to this isomer and the susceptibility of the fetus to
develop cleft palate was determined. The homozygous fetuses (+/+), which had
abundant P-gp, were totally insensitive to this teratogen whereas the homozygous
fetuses (-/-), which were deficient in P-gp, were completely susceptible to developing
cleft palate. The heterozygote fetuses (+/-) had a moderate effect due to intermediate
expression levels of P-gp [13]. Since mice have two mdr genes, mdr1a and mdr1b, it
was thought that mdr1b would be upregulated in the mdr1a KO mice as a
compensatory mechanism. Therefore to nullify all mdr activity, Smit et al. used KO
mice in which both the mdr genes, mdr1a and mdr1b, were disrupted. These mice
were used to study the transport of P-gp substrates digoxin, saquinavir and paclitaxel
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in pregnant heterozygous mdr mice [10]. They demonstrated that the placental P-gp
reduced the transfer of drugs to the fetus with the most reduction found in the WT
fetuses (mdr1a+/+ / 1b+/+) as compared to heterozygous fetuses (mdr1a+/- / 1b+/-) and
KO fetuses (mdr1a-/- / 1b-/-). They further demonstrated that after oral administration
of P-gp inhibitors like PSC833 or GF120918, drug levels in WT mice were
comparable to KO mice and much higher than WT vehicle treated mice. These
studies demonstrate the importance of placental P-gp in limiting the fetal exposure of
potential chemical teratogens. It also suggests that modulation of placental P-gp can
increase the transfer of drugs across the placenta to the fetus if the fetus is the patient
and transfer is desirable for a therapeutic outcome.

1.2.2. Substrates and Inhibitors of P-gp
The phenomenon of multidrug resistance found during the treatment of
cancer has been partly attributed to transporters such as P-gp. P-gp is involved in the
transport of a large variety of drugs used for numerous disorders including cancer
(doxorubicin, vinblastine, paclitaxel) and AIDS (amprenavir, saquinavir).

An

extensive list can be found at www.aidsinfonyc.org. These drugs differ not only
functionally but also structurally. Most of the drug substrates are hydrophobic but
can be neutral or positively charged. To understand the broad substrate specificity,
researchers have carried out mutation analysis, which demonstrated that mutations in
the transmembrane domains affect P-gp functionality. These results suggest that the
binding sites are broad regions of recognition [14]. In addition, Martin et al. [15]
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have demonstrated, using several substrates and modulators of P-gp in radioligand
binding studies, that P-gp has a minimum of four distinct drug binding sites and there
is an allosteric interaction between the sites.
Inhibition of P-gp to increase the effectiveness of cancer chemotherapeutic
agents is thought of as one route of decreasing multidrug resistance.

The first

generation of P-gp inhibitors (cyclosporin A, verapamil) were drugs that were used
for other therapeutic purposes.

Due to toxicity issues, a second generation of

inhibitors for e.g. PSC833, which are analogs of the first generation agents for e.g.
cyclosporin A were developed. LY335979 is by far the most potent and selective
inhibitor of P-gp. A thorough review of interactions of P-gp with its substrates and
inhibitors has been presented by Litman et al. [14].

1.2.3. Induction, regulation and drug-drug interactions of P-gp
Many P-gp substrates are also P-gp inducers.

In LS180/WT and its

adriamycin resistant subline LS180/AD50, P-gp was upregulated after treatment with
various drugs including rifampin, phenobarbital, clotriamazole, reserpine, midazolam,
nifedipine and isosafrole. An increase in ABCB1 mRNA on treatment with rifampin
and reserpine suggested that P-gp is upregulated at the transcriptional level rather
than at the post-translational level [16]. ABCB1 mRNA was also upregulated by
polycyclic aromatic hydrocarbons (PAHs) like 3-methylcholanthrene (3-MC) and
2,3,7,8-tetrachlorodibenzo-p-dioxin

(TCDD)

in

primary

human

hepatocytes.

However a polymorphic inducibility was seen where 3-MC and TCDD induced
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ABCB1 mRNA in only 62% and 55% of the preparations respectively. These results
suggest that although aromatic hydrocarbons upregulate ABCB1, the induction does
not occur via the classical Ah receptor pathway [17].

Polli et al. [18] have

demonstrated that HIV protease inhibitors like amprenavir and nelfinavir are not only
substrates of P-gp but also induce P-gp.

Western blot analysis revealed that

amprenavir and nelfinavir both increased the expression of intestinal P-gp but not of
hepatic P-gp in rats, suggesting a tissue specific induction. The difference in P-gp
induction could also be due to reduced concentrations of these drugs reaching P-gp in
the liver as they might be metabolized by hepatic CYP3A4, which itself is induced by
these drugs.
Due to its wide substrate specificity and inducibility, P-gp plays a very
important role in drug-drug interactions. In-vitro experiments and animal studies
have shown that fexofenadine [19] and digoxin [20;21] both are substrates for P-gp
and are primarily excreted unmetabolized. Concomitant administration of rifampin
with digoxin reduced the oral bioavailability of digoxin in healthy males by 30% and
a 3.5 fold increase was seen in intestinal P-gp expression [22]. Similarly Hamman et
al. have shown that rifampin therapy reduced the bioavailability of fexofenadine,
which they attributed to the induction of intestinal P-gp [23].
Recent studies have helped us understand the mechanism of regulation of
P-gp at the molecular level. Synold et al. [24] have recently shown that the pregnane
X receptor (PXR), a nuclear hormone receptor, regulates drug efflux by activating the
expression of the ABCB1 gene. Paclitaxel (taxol), a commonly used antineoplastic
agent is an efficient and selective activator of PXR and induces ABCB1 mediated
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drug efflux. However, docetaxel (taxotere), an analog of paclitaxel, did not activate
PXR or induce the ABCB1 mediated drug efflux. Ecteinascidin-743 (ET-743) is an
antineoplastic agent and has been shown to inhibit trichostatin-induced transcription
of ABCB1 [25;26]. Synold et al. [24] found that ET-743 can repress the ligand
mediated activation of PXR thus inhibiting the transcriptional activation of ABCB1.
In addition, Geick et al. found PXR response elements, essential for ABCB1 induction
by rifampin, to be present in the upstream region of human ABCB1 [27]. These
studies support the role of PXR in regulation of P-gp, however, it might not be solely
responsible for P-gp induction and other regulatory pathways may exist given that Pgp is also induced by some Ah receptor ligands.

1.2.4. Genetic Polymorphism in P-gp
As mentioned above, phenotypic variability was reported in the induction
of P-gp by PAHs [17]. In addition, substantial interindividual variability was seen in
expression of hepatic P-gp within and between males and females [28].

Also,

disposition of P-gp substrates varies between individuals [29;30] and this could be
important for drugs with narrow therapeutic indices. These reports underscore the
importance of genotyping studies to determine if any polymorphisms exist that may
explain the observed inter-individual differences. In-vitro studies have suggested that
amino acid changes in the ABCB1 gene leads to altered activity [31;32]. A total of 15
polymorphisms were identified by Hoffmeyer et al. in the ABCB1 gene in a
Caucasian population. The authors demonstrated a significant correlation between
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the single nucleotide polymorphism (SNP) at exon 26 (C3435T) and P-gp expression
and activity in the duodenum.

Individuals with the T/T allele had lower P-gp

expression and higher plasma concentrations of digoxin [33].

P-gp genotyping

studies in Japanese women showed that in addition to the SNP at exon 26 (C3435T),
which was present in 93.8% of women in the study, these individuals also had a SNP
at exon 21 G2677 (A/T) [34]. This suggests an association between these two SNPs.
Later, Kim et al. [35] found the following 3 SNPs to be present simultaneously in 62
% of European Americans and 13% of African Americans: C1236T in exon 12,
G2677T in exon 21 and C3435T in exon 26. Using fexofenadine as a probe drug,
these individuals were phenotyped for P-gp activity. The results suggested that the
individuals who had the T/T homozygous allele in both exon 21 and exon 26 had
lower plasma concentrations of fexofenadine suggesting an increased expression of Pgp as compared to the individuals containing the homozygous G/G and C/C allele in
exon 21 and exon 26, respectively. These results are however contradictory to the
results published by Hoffmeyer et al. [33] and Tanabe et al. [34]. Thus, the effects of
genetic polymorphisms with respect to the direction of change in P-gp expression and
activity are still unclear. Further studies are needed to understand the effect of these
polymorphisms not only on the level of expression but also the functional activity of
P-gp.
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1.3. ABCP (BCRP / MXR)
Placenta-specific ATP binding cassette gene (ABCP) [36] also known as
breast cancer resistance protein (BCRP) [37] or mitoxantrone resistance associated
protein (MXR) [38], is encoded by ABCG2 which belongs to the ABCG subfamily.
ABCG2 gene is located on chromosome 4q22.

ABCP is a 655 amino acid

transmembrane protein with a molecular weight of 70 kDa. ABCP utilizes energy
from ATP hydrolysis to function as an efflux transporter.

It has only 6

transmembrane domains and an intracellular ATP binding domain towards the Nterminal (Figure 1.1). ABCP exists as a half transporter and is half the size of other
ABC transporters like P-gp which has 12 transmembrane domain and two ATP
binding domains. The half transporters usually dimerize to become functional and
ABCP is assumed to be a functional dimer. Though no dimerization partner has been
identified so far, current transfection data suggest it is functional as a homodimer
[14].

It was reported that ABCP migrates as a 70 kDa protein under reducing

conditions and as a 140 kDa complex under non-reducing conditions. These results
suggest that ABCP forms a homodimer via the disulfide linkage [39].

1.3.1. Substrates and Inhibitors of ABCP
ABCP offers resistance to a variety of substrates and exhibits considerable
substrate overlap with P-gp, as shown in Figure 1.2 adapted from Litman et al. [14].
Mitoxantrone and topotecan are good substrates for ABCP and overexpression of
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ABCP has been reported in both mitoxantrone and topotecan resistant cells [40;41].
A number of functional assays have been developed to determine the functional
activity of ABCP and to screen for drugs that interact with the protein. Some of the
substrates that are transported by ABCP are the anthracyclines, SN-38 [42],
bisantrene, rhodamine 123, LysoTracker Green, prazosin and its fluorescent analog
BODIPY-prazosin [43].
Fumitermorgin C (FTC) [44] and GF120918 [45] are effective inhibitors
of ABCP and increase the intracellular accumulation of ABCP substrates in ABCP
overexpressing cells. FTC is a potent and selective inhibitor of ABCP whereas
GF120918 is a potent inhibitor but not selective and is know to inhibit P-gp as well.
More than 20 analogs of FTC have been analyzed for their inhibitory action on ABCP
but none had equal or better activity or selectivity than FTC for ABCP [46].
Recently, it was demonstrated that estrone and 17β-estradiol also inhibit ABCP and
increase the intracellular accumulation of topotecan in drug resistant cells that
overexpress ABCP [47].
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P-gp

ABCP
VER
VBL
VCR
TXL
COL

DOX
DNR
CPT-11
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PRA
TOP
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Figure 1-2 Venn diagram showing the substrate overlap between P-gp and ABCP
Abbreviations: BIS, bisantrene; CPT-11, Topotecan; DNR, daunorubicin; DOX,
doxorubicin; EPI, epirubicin; LYS, LysoTracker; MX, mitoxantrone; PRA, prazosin;
RHO, rhodamine 123; SN-38, metabolite of CPT-11; TXL, taxol; TOP, topotecan; VBL,
vinblastine; VCR, vincristine; VER, verapamil. Figure adapated from Litman et al. [14].
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1.3.2. Tissue distribution, location and function of ABCP
Observation of drug resistance and reduced drug accumulation in
multidrug tumor cells which did not show overexpression of P-gp or MRPs led to the
discovery of ABCP, a new member of ABC superfamily of transporters. These cell
lines are derived from breast cancer [37], ovarian carcinoma [41] and colon
carcinoma cells [44].

Using immunohistochemical staining, ABCP has been

predominantly localized to plasma membranes [48]. Apart from being expressed in
cancerous tissue, ABCP has also been reported to be present in normal tissues.
Tissue distribution of ABCG2 mRNA was determined by northern blotting and found
to be present predominantly in placenta and to a lesser extent in brain, small intestine,
liver, colon ovary, testis and prostate [37]. ABCP protein has also been reported to be
expressed prominently in placenta, liver, small intestine and colon of humans [49].
This expression corresponded with ABCG2 mRNA levels measured by RT-PCR. The
murine breast cancer resistance protein (bcrp1) is highly homologous to human
ABCP with 81% amino acid identity [50]. The bcrp1 mRNA was however found to
be highly expressed in kidney and to a lesser extent in placenta as compared to
humans [51]. A new multidrug resistance protein has been identified in porcine brain
capillary endothelial cells that is closely related to ABCP with 86% amino acid
identity [52]. The tissue distribution of ABCP is similar to P-gp distribution and
suggests it may play a role in the absorption, distribution and elimination of drugs.
Its substantial expression in placenta also suggests ABCP may serve as a protective
barrier which prevents the transport of its substrates across the placenta and to the
fetus. In order to understand the role of bcrp in placenta, Jonker et al. [51] measured
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the bioavailability of topotecan in fetuses of wild type mice and mdr1a/1b knockout
mice. The mdr1a/1b knockout mice were used to control for the contribution of P-gp,
since some overlap in substrate specificity exists. The authors reported that the
bioavailability of topotecan in the presence of GF120918, an ABCP and P-gp
inhibitor, was six fold higher in KO mice and nine times more in the WT mice as
compared to the respective vehicle treated mice.

Also, a two fold higher fetal

exposure of topotecan was seen in KO mice treated with GF12098 than in vehicle
treated KO mice [51]. These results suggest an important role for bcrp in fetal
exposure to drugs. To date, there are no reports on functionality of ABCP in human
placenta. However, with the knowledge that ABCP is highly expressesed in human
placenta and that there is homology between the mouse bcrp and human ABCP, one
can assume that ABCP in addition to P-gp plays an important role in limiting the fetal
exposure to various xenobiotics during pregnancy.

1.3.3. Mutations / polymorphisms in ABCP
Of the 9 cell lines studied, Rhodamine 123, a substrate for ABCP, was
transported in some but not all ABCP overexpressing cells whereas mitoxantrone was
transported in all cell lines. On seqencing the genomic DNA, mutations in the amino
acid at position 482 were found. The wild type ABCP has an arginine (R) at postion
482 whereas some cells had either threonine (T) or glycine (G) at this position. The
mutated cells (R482T or R482G) were able to carry out the transport of rhodamine
123 in contrast to the wild type cells. The transport of doxorubicin also was shown to
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be affected by the mutations. These results suggest that the amino acid at position
482 may be critical in binding of the substrate to the transporter, thus affecting
substrate transport. It should also be noted that the mutational effects observed are
substrate dependent. As these mutations change the substrate specificity they may
lead to alterations in drug resistance phenotype [53]. Recently, similar results were
seen in mouse cell lines overexpressing bcrp1. Mutations at position 482 were seen,
however, in murine cells arginine was replaced by methionine (M) and serine (S) [54]
as opposed to threonine and glycine in humans. Genotyping studies to determine if
such polymorphisms exist in normal human tissues are needed and should be
accompanied by phenotyping studies to understand the impact of these amino acid
changes in function of ABCP. Recently, Zamber et al. [55] performed an ABCP
genotyping study using human intestinal samples from 11 different ethnic populations
and have reported the presence of several SNPs, with G34A and C421A being the
two most frequent SNPs observed. Interestingly, the mutations observed in the drug
selected cell lines resulting in an amino acid change at position 482 were not detected
in any of the human intestinal samples and thus were attributed to acquired mutations
due to drug selection. There was significant variation in the expression of ABCP
mRNA and protein between individuals and on an average expression was higher in
females than males.

However, no correlation was observed between the most

frequent polymorphisms and the level of ABCP expression.

Whether these

polymorphisms have an effect on ABCP function in humans is yet to be determined.
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1.4. Cytochrome P450 1A1 (CYP1A1)
The human CYP1 family contains CYP1A1, CYP1A2 and CYP1B1
[56;57].

CYP1A2 is found primarily in hepatic tissue whereas CYP1A1 and

CYP1B1 are extrahepatic in nature. CYP1A1 and CYP1A2 belong to the CYP1A
subfamily and are approximately 68% identical in their sequence [58].
CYP1A1, also known as aromatic hydrocarbon hydroxylase, is responsible
for metabolism of environmental carcinogens such as polycyclic aromatic
hydrocarbons (PAH). Benzo[a]pyrene, a PAH, is principle constituent of cigarette
smoke. It is a procarcinogen and is metabolized by CYP1A1 to mutagenic and
carcinogenic compounds. CYP1A1 is highly inducible by PAHs, cigarette smoking
and polychlorinated biphenyls (PCB).

The mechanism of induction of CYP1A

enzymes is well studied and understood.

The inducing agent (ligand) binds to

cytosolic aromatic hormone receptor (Ah receptor) and this receptor is translocated to
the nucleus where it binds to Ah receptor nuclear translocator (ARNT) protein. This
complex then binds to the DNA of the CYP1A1 gene and enhances its rate of
transcription. There is inter-individual variability in the induction of CYP1A1 which
might be related to the genetic differences in the Ah receptor expression [59].
Of the CYP1A family, CYP1A1 and CYP1B1 are found in human
placenta. CYP1A2 is not found in placenta; however, its mRNA can be detected in
the first trimester (10-12 weeks of gestation) of pregnancy. CYP1A1 mRNA as well
as the protein has been found in full term placentas [60;61]. The 7-ethoxyresorufin
O-deethylase (EROD) reaction is mainly catalyzed by CYP1A1 and is used as an
activity marker for this enzyme.

Constitutive CYP1A1 activity is very low or
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unmeasurable in placentas, however, this activity increases with maternal cigarette
smoking [62]. CYP1A1 gets induced to a variable extent depending on stage of
pregnancy with the highest activity being seen at term [63]. Immunohistochemical
analysis has shown that the cigarette smoke induced CYP1A1 is localized over both
synctiotrophoblastic and cytotrophoblastic areas [64] of the placenta.
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1.5. Placenta
The placenta is the sole link between the mother and the fetus. It carries
out the transport of essential nutrients, oxygen and water from mother to the fetus as
well as removing waste products from the fetus. It performs the necessary functions
of several fetal organs such as the liver, lungs, kidney etc. until these organs are fully
developed. The placenta is a disc shaped tissue and has two plates namely chorionic
and basal plate which faces the fetus and mother, respectively [65]. Villous tissue
present between these two plates is perfused with maternal blood. The placental villi
are tree like structures originating from the chorionic plate and are lined with
trophoblastic cells [66]. Transfer of xenobiotics across the placenta proceeds both
passively and via various transporters that are expressed in villi in a polarized fashion.
These transporters are expressed differentially in the maternal-facing brush border
and the fetal-facing basal membrane of syncytiotrophoblast (ST) cells, which is
known as the functional unit of placenta. ST is multinucleated and is formed as the
pregnancy advances by the fusion of uninucleated cytotrophoblastic cells. In addition
to physiological substrates, the transporters present in the membranes of ST also
transport xenobiotics which include therapeutic agents, environmental pollutants and
drugs of abuse. Therapeutic agents used to treat the mother may cross the placental
barrier and have untoward effects on the fetus. On the other hand, in cases such as
where the fetus is HIV infected, placental transfer of therapeutic agents is desirable
for a positive therapeutic outcome. In addition to transporters, there are also some
drug metabolizing enzymes present in the placenta which alter the passage of
xenobiotics across the placenta. These enzymes primarily metabolize xenobiotics to
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make them more water soluble and thus increase their elimination; however, toxic
and / or reactive metabolites may also be produced.
The brush border membrane of the ST faces the mother and is in direct
contact with maternal blood whereas the basal membrane faces the fetal blood
circulation. The brush border (microvillus) membrane is made up of microvilli that
increase the surface area of the membrane. There is evidence of efflux transporters,
belonging to the ABC superfamily of proteins, such as P-gp, ABCP and some of the
MRPs, being present in the microvillus membrane of the placenta. Due to their efflux
nature, these transporters expressed in microvillus membranes can pump xenobiotics
back to mother and thus may prevent fetal toxicity.
P-gp is abundantly expressed in human placental trophoblast cells [9;67]
and this expression is selectively seen in trophoblast cells of first trimester placenta.
In full term placenta, P-gp was found in Hofbauer cells and placental macrophages.
However, Nakamura et al. also demonstrated the presence of P-gp in trophoblasts
from full term placenta [68].

Uptake of radiolabeled vincristine in microvillus

membrane vesicles isolated from trophoblast cells confirmed the expression of active
P-gp in the placenta. However, these investigators reported a smaller size P-gp (160
kDa) to be present in trophoblast, whereas others have reported a 170 kDa P-gp in
primary human cytotrophoblasts [69] which could be due to differences in posttranslational modifications such as glycosylation.

Primary cultures of human

cytotrophoblasts and BeWo cells, a choriocarcinoma cell line, have also been used to
study the functional expression of P-gp [69;70].
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Apart from P-gp, other multidrug transporters are also present in placenta.
With the help of sensitive molecular techniques, multidrug resistance associated
protein (MRP) was found to be present in human placenta. At least 3 different MRP
mRNAs have been identified in placenta [71]. MRP1 and MRP5 are present and
functionally active in BeWo cells [72] and are involved in the transport of
unconjugated bilirubin. The most recently discovered ABC efflux transporter, ABCP
(BCRP / MXR), is reported to be highly expressed in the plasma membrane of
syncytiotrophoblastic cells of the placenta [73]. High endogenous expression of
ABCP was also found in the human choriocarcinoma cell lines JAR, JEG-3 and
BeWo [74]. However, there are no reports on the functionality of ABCP in human
tissues and whether this protein is functional in placenta is yet to be determined.

1.6. Effect of smoking on placenta and placental enzymes and
transporters
Cigarette smoking has been associated with adverse outcomes during
pregnancy including changes in function and structure of the placenta. Furthermore,
increased fetal morbidity and mortality have been reported due to maternal smoking.
Morphologically, changes such as thickening of the trophoblastic cells and decrease
in volume density of fetal capillaries within terminal villi have been observed in
smokers [75].
Smoking and associated polycyclic aromatic hydrocarbons (PAHs) can
affect drug metabolizing enzymes expressed in placenta. The constitutive expression
23

of CYP1A1 is low in placenta but is readily induced by xenobiotics. PAHs found in
cigarette smoke are good inducers of CYP1A1, and high and variable CYP1A1
activity has been reported in placental microsomes from smokers as compared to nonsmokers [62].
To date, the effect of smoking on efflux transporters expressed in placenta
has not been reported. P-gp, however, has been shown to be induced by various
PAHs in rat and mouse liver. Of the PAHs studied, 3-MC and 2-acetylaminofluorene
induced P-gp mRNA levels in primary cultures of hepatocytes in rats, however,
TCDD was unable to induce P-gp mRNA levels at relevant concentrations of TCDD
[76]. Similarly, in mouse liver, P-gp mRNA levels were induced by 3-MC but not by
TCDD [77]. Interestingly, 3-MC and TCDD both induced P-gp mRNA levels in
primary cultures of human hepatocytes. However, a phenotypic variability was seen
in the induction [17] as only 62% and 55% of the primary hepatocyte cultures showed
induction after treatment with 3-MC and TCDD respectively. Thus, in-vitro animal
and human studies suggest that PAHs induce P-gp mRNA in liver, however, whether
similar induction occurs in placenta is not known. In addition, PAH benzo-[a]pyrene, apart from being a substrate for CYP1A1, is also a substrate for P-gp [78].
Thus, analogous to the induction of CYP1A1, there could possibly be induction of Pgp levels in placentas of women who smoke during pregnancy, resulting in a
protection of the fetus from the harmful effects of cigarette smoke constituents. Thus,
we hypothesized that smoking might increase P-gp levels in human placenta. ABCP,
another efflux transporter expressed in placenta, is also believed to play a protective
role in placenta similar to P-gp. However there are no reports of functional studies of
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ABCP in human placenta and its regulation by cigarette smoke constituents. Thus, we
studied the function and expression of P-gp and ABCP in placentas from smokers and
non-smokers.

1.7. Specific aims of this research

1. Compare levels of P-gp activity and expression in human placentas from smokers
and non-smokers.
2. Correlate levels of P-gp and CYP1A1 in human placentas from smokers and nonsmokers.
3. Compare levels of ABCP activity and expression in human placentas from
smokers and non-smokers.
4. Evaluate the induction of P-gp by various xenobiotics in choriocarcinoma and
colon carcinoma cell lines.
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CHAPTER II
2. EXPERIMENTAL
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2.1. Patient Selection
Subjects were recruited through the Obstetrics and Gynecology Department at
Ruby Memorial Hospital at West Virginia University. Placental samples were obtained
using a protocol approved by the West Virginia University Institutional Review Board for
the Protection of Human Research Subjects (Figure 2.1 and 2.2). Participants provided
informed written consent prior to obstetric delivery. Placentas were collected from
women (ages 18-36 years) who were full term (38 weeks and more). Subjects were
smoking and non-smoking females with no concurrent disease states. Smoking status
was determined via patient interview.

2.2. Tissue Collection
Placentas were collected and processed immediately after delivery.

Two

triangular wedges extending from center of the placenta to the placental margin were
removed for processing. One piece was placed in a plastic bag, appropriately labeled and
frozen at -80°C for later preparation of placental microsomes. The other piece was
immediately processed to prepare the membrane vesicles.
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Figure 2-1 Consent Form (Page 1)
Consent form for placental transport of drugs approved by West Virginia University
Institutional Review Board for the Protection of Human Research Subjects
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Figure 2-2 Consent Form (Page 2)
Consent form for placental transport of drugs approved by West Virginia University
Institutional Review Board for the Protection of Human Research Subjects
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2.3. Preparation of Microvillus and Basal Membrane Vesicles
Microvillous membrane vesicles (MVM) and basal membrane vesicles (BMV)
were prepared simultaneously from the same placenta within 30 min of delivery using a
homogenization and differential centrifugation technique conducted according to the
methods of Illsley et al. [79]. The tissue was cut into small pieces and washed several
times in 0.9% NaCl. The washed tissue was further minced finely and suspended in 3
volumes of buffer 1. The suspension was homogenized in 25 ml aliquots for 2 min using
a Virtisher tissue homogenizer and this was labeled as homogenate 1 which was
centrifuged at 10,000 g for 15 min. The supernatant (supernatant 1) was collected and
the pellet resuspended in buffer 1, homogenized (homogenate 2) and centrifuged again.
Both supernatant fractions were then combined, filtered through gauze and centrifuged at
47,500 g for 1 h. The pellet was resuspended in buffer 1 (15 mg/ml) and to this MgCl2
was added (12 mM final concentration). The mixture was stirred on ice for 20 min and
centrifuged at 2500 g for 15 min. The supernatant and Mg2+ aggregated pellet was
further processed to get the MVM and BMV respectively.
centrifuged at 47,500 g for 30 min.

The supernatant was

The obtained pellet (MVM) was washed and

resuspended in buffer 2 after passage through a 25-gauge needle, aliquoted and stored at 80°C. The Mg2+ aggregated pellet was resuspended in buffer 2, homogenized thoroughly
and 15 ml was layered onto a sucrose step gradient. The step gradient was constructed in
40ml Beckman SW 28 centrifuge tubes using a bottom fraction (6 ml) with density 1.190
gm/cm3 and a middle fraction (17 ml) with density 1.165 gm/cm3. The gradient was
centrifuged for 1 hour at 141,000 g using a Beckman SW 28 swing-out rotor with a slow
acceleration and deceleration through 140 rpm. The resulting fraction at the interface of
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the bottom and middle steps was collected. This fraction was diluted with 10 volumes of
buffer 2, homogenized and centrifuged at 47,500 g for 30 min. The pellet (BMV) was
resuspended in buffer 2 after passage through a 25-gauge needle, aliquoted and stored at 80°C. The entire procedure was carried out at 4°C.

Buffer 1:
Buffer 1 consists of 10 mM Tris HCl – Hepes (pH 7.0), 250 mM sucrose, 5 mM EGTA, 5
mM EDTA and 1 mM PMSF.
Buffer 2:
Buffer 2 consists of 10 mM Tris HCl - Hepes (pH 7.4) and 250 mM sucrose.

2.4. BCA Protein Assay
Membrane vesicle protein concentrations were determined using the BCA protein
assay kit from Pierce. The assay was carried out in a 96 well, flat bottom polystyrene
(clear) microtiter plate. Samples were diluted 1:10 (10 µL sample and 90 µL of distilled
H2O) and 1:20 (5 µL sample and 95 µL of distilled H2O) with water and then vortexed.
20 µL of standards (Bovine serum albumin 125 µg/mL – 2000 µg/mL) and diluted
samples were pipetted in appropriate wells (n = 3). The BCA reagents were prepared
according to the manufacturers instructions and 200 µL/well was added by means of an
Eppendorf repeating pipettor.

The plate was shaken to mix the solutions and then

incubated at 37°C for 30 min. After allowing the plate to cool to room temperature, the
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absorbance was read at 562 nm on a Thermomax plate reader using Softmax Pro
software.

BCA protein reagents
Immediately prior to use, mix 1 part of reagent B (0.5 ml) with 50 parts of reagent A (25
ml).

2.5. Sialic Acid Assay for Sidedness or Orientation of Membrane
Vesicles
The percentage of inside-out vesicles was determined by the accessibility of
sialidase to sialic acid in the presence and absence of detergent. Briefly, aliquots of
vesicles containing 100 - 300 µg of protein in 50 µL were incubated at 37°C for 30 min
with an equal volume of sialidase reagent with or without 0.2% Triton X-100 (detergent)
[80]. The samples were centrifuged at 10,000 rpm for 5 min and the supernatant used to
measure the sialic acid released using a combination of the methods of Warren et al. [81]
and Aminoff et al. [82]. Briefly, 0.5 ml of sample / standard was incubated at 37°C with
0.25 ml of the periodate reagent for 30 min. At the end of 30 min, the tubes were taken
out of water bath and 0.2 ml of sodium arsenite solution was added to reduce the excess
periodate. The tubes were then vortexed until the yellow color of the liberated iodine
disappeared (2 min). As soon as the yellow color disappeared, 2 ml of thiobarbituric acid
reagent was added, tubes were capped, vortexed and placed in a boiling water bath for 10
min. At the end of 10 min, the tubes were placed in ice water for 5 min and then shaken
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with 3 ml of cyclohexanone. The tubes were then centrifuged at 3000 rpm for 3 min and
the upper organic layer collected. The organic layer was transferred to a cuvette and the
absorbance was measured at 549 nm using a Hitachi U-2000 UV spectrophotometer. The
amount of sialic acid released in the samples was calculated from the slope of the
standard curve generated using N-acetylneuraminic acid (20 µg/ml – 320 µg/ml).

Calculations
  SialicAcid Re leased (− det ergent ) 

× 100 
% Inside − OutVesicles = 100 −  

  SialicAcid Re leased (+ det ergent ) 


Periodate Reagent
Periodate reagent consists of 0.2 M sodium m-periodate, 9 M phosphoric acid.
Dissolve sodium m-periodate in water first and then add the phosphoric acid.
Store at room temperature.

Sodium arsenite reagent:
Sodium arsenite reagent consists of 0.5 M sodium sulfate, 0.1 M H2SO4 and 10% sodium
arsenite.
Store at room temperature.

Thiobarbituric acid reagent:
Thiobarbituric acid reagent consists of 0.1 M thiobarbituric acid with the pH adjusted to
pH 9.0 with 10 N NaOH.
Store at 4°C in a refrigerator.
Sialidase Stock:
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Type VI neuraminidase from Clostridium perfringens (Sigma) is stored as 1 mg/ml
solution in 0.3 mg/ml bovine serum albumin in refrigerator.
Sialidase Reagent:
0.1 mg/ml of sialidase in 0.1 M Tris-acetate buffer pH 5.0. Store in refrigerator.
Sialidase and Triton reagent:
Sialidase reagent + 0.2% (v/v) Triton X-100. Store in refrigerator.

2.6. Alkaline Phosphatase Assay
Alkaline phosphatase is a marker enzyme localized in the microvillus membrane
of cells. It catalyzes the formation of p-nitrophenol from p-nitrophenylphosphate [83].
An alkaline phosphatase assay can be used to determine the enrichment of microvillus
membrane when isolating membranes from cells or tissue homogenates [79] as well as to
measure the orientation of membrane vesicles.

2.6.1. For determination of enrichment of the microvillus membrane
To determine the enrichment of the microvillus membrane, aliquots from various
stages of the membrane vesicle preparation procedure were saved including homogenate
1, supernatant 1, homogenate 2and the final microvillus membrane pellet. The protein
concentration of these samples was determined using the BCA protein assay. All the
above mentioned fractions and the final microvillus membrane pellet were diluted to
achieve a protein concentration of 2.5 mg/ml and further diluted to 1:2000 with
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diethanolamine / MgCl2 buffer. 20 µL of the diluted samples were aliquoted into a 96
well plate and to this 50 µL of diethanolamine / MgCl2 buffer containing 5 mM pnitrophenylphosphate were added. After mixing, the plate was incubated at 37°C for 30
min and the absorbance read at 405 nm using a Thermomax plate reader. The amount of
p-nitrophenol formed was calculated from a standard curve generated using p-nitrophenol
(40µM – 1280 µM) dissolved in diethanolamine / MgCl2 buffer. The fold enrichment in
the final microvillus membrane pellet was calculated relative to the formation of pnitrophenol in the homogenate 1 sample.
2.6.2. For determination of orientation of vesicles
Membrane vesicle samples were diluted to 1:10,000 with diethanolamine / MgCl2
buffer with or without 0.2% Triton X-100 (detergent). The alkaline phosphatase activity
was measured as mentioned above. The percentage of inside-out vesicles was calculated
from the following equation.

  p − nitrophenolFormed (− det ergent ) 

% Inside − OutVesicles = 100 −  
× 100 

  p − nitrophenolFormed (+ det ergent ) 


Diethonolamine / MgCl2 buffer (pH 9.8)
Diethonolamine / MgCl2 buffer consists of 1 M diethanolamine and 0.24 mM Magnesium
chloride hexahydrate.
Dissolve magnesium chloride in half the volume of water first and then add the
diethanolamine and adjust the pH to 9.8 with HCl. Store at 4°C.
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2.7. Uptake Assay: Developmental Work and Final Protocol
Since P-glycoprotein and ABCP are efflux transporters, membrane vesicles with
inside-out orientation are useful in measuring the accumulation of radiolabeled substrate.
The active uptake is determined by measuring the uptake in the presence and absence of
ATP. By measuring the time and osmotic dependent uptake we can distinguish between
the actual uptake of the substrate across the membrane and non-specific binding of
substrate to the membrane [84]. Vinblastine and mitoxantrone were used as model
substrates for determining the activity of P-gp and ABCP, respectively.

Membrane vesicles were diluted using the vesicle dilution buffer to a
concentration of 2.5 mg/ml. After dilution, the vesicles were syringed 10 times using a
25-gauge needle. Forty-five µL of transport buffer (with or without ATP) containing
substrate and an ATP regenerating system was aliquoted into glass test tubes and
maintained at 37°C. The diluted vesicles were also placed in a water bath at 37°C.
Following a 5 min pre-incubation, the reaction was initiated by addition of 10 µL of
diluted vesicles to each tube at 30 sec intervals. At the end of the incubation period (10
min for vinblastine and 6 min for mitoxantrone), the reaction was quenched by addition
of 3 ml of ice-cold quench buffer. The quenched samples were immediately filtered
through 0.45 µm nitrocellulose filters (Whatman), pre-soaked in 3% bovine serum
albumin, using a Millipore 1225 Sampling Manifold. The filters were then washed with
an additional 3 ml of ice-cold quench buffer and then transferred with forceps to a
scintillation vial. Ten ml of Scintiverse® BD was added and the vials were shaken.
They were allowed to sit for a few minutes before the samples were read using a
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Beckman scintillation counter. The cpm obtained from the instrument were then used in
the following equation to calculate the uptake as pmol / mg of protein. The ATP
dependent uptake was the difference between the uptake in the presence and absence of
ATP.

 CPM × pmolofSubstrateAdded 

pmolof [ 3H ] − substrate / mgofprotein = 
 TotalCPMAdded × mgofprotein 

Buffer 2
Buffer 2 consists of 10 mM Tris-HCl, pH 7.4 and 250 mM sucrose.

Transport buffer
Transport buffer consists of 10 mM creatine phosphate, 100 µg / ml creatine
phosphokinase, 10 mM magnesium chloride hexahydrate and 4 mM ATP (added only in
+ ATP transport buffer). The volume was made up with buffer 2.
For vinblastine uptake assay:
20 nM [3H]-vinblastine (stock of 0.25 µCi / µL) + enough cold vinblastine (5 µM stock in
buffer 2) to make a final concentration of 100 nM.
For mitoxantrone uptake assay;
50 nM [3H]-mitoxantrone (stock of 1 µCi / ml) + enough cold mitoxantrone (5 µM stock
in buffer 2) to make a final concentration of 100 nM.
Vesicle dilution buffer:
Vesicle dilution buffer consists of 10 mM creatine phosphate, 100 µg / ml creatine
phosphokinase and 10 mM magnesium chloride hexahydrate. The volume was made up
with buffer 2.
Quench buffer: Ice-cold buffer 2
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2.7.1. Time Dependent Uptake Assay
For determining the time course of the reaction, the membrane vesicles were
incubated with vinblastine in transport buffer as outlined above and the reaction was
quenched at 0, 1, 2, 4, 6, 8, 10, 15, 20, 30 and 60 min. The uptake was measured in the
presence and absence of ATP.

2.7.2. Osmotic Dependent Uptake Assay
To determine whether the uptake was sensitive to osmolarity changes, increasing
concentrations of sucrose were added to the transport buffer.

The transport buffer

contained 250 mM, 333 mM, 500 mM and 1 M sucrose with rest of the additives
remaining the same. Vinblastine uptake was measured in the presence and absence of
ATP for 10 min in triplicate. The remainder of the procedure was followed as outlined
above in the uptake protocol.

2.7.3. Determination of type of filters and filter soaking media to block the
non-specific binding
Two different types of filters, nitrocellulose (0.45 µm) and glass fiber filters (GF /
F), were used with different types of soaking media: 10% fetal bovine serum, 3% bovine
serum albumin, 5 µM unlabeled vinblastine (for 5 min and 1 h). Also, 1 µM and 10 µM
unlabeled vinblastine was used in the quench media to determine if it would decrease the
non-specific binding of [3H]-vinblastine to the filters.
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2.7.4. Inhibition studies
The uptake assay was carried out in the presence of inhibitors of P-gp and ABCP
to assess the involvement of the transporters in the uptake of vinblastine and
mitoxantrone, respectively. Inhibition studies were also carried out to determine if either
protein interfered with the transport of the model substrate of the other protein.
The mitoxantrone uptake assay was carried out in presence of 10 µM
fumitremorgin C (FTC), a selective inhibitor of ABCP [44] and 10 µM of verapamil, a
known P-gp inhibitor. Likewise, uptake of vinblastine was determined in presence of
verapamil (10 µM and 100 µM) and 10 µM FTC.

2.8. Immunoblotting Studies for Detection of P-gp and ABCP
Placental membrane vesicles were added to a volume of loading buffer to achieve
a concentration of 2 µg/µL. The broad range molecular weight markers (Bio-Rad) and
samples were boiled for 10 min and 10 µg of protein (sample) was loaded on 15 well 7%
NuPAGE Tris-acetate mini gels (Invitrogen). Electrophoresis was carried out using a
Surelock mini cell apparatus (Invitrogen) for 1 h 30 min at 130 volts. Proteins were then
transferred to a nitrocellulose membrane for 1 h 30 min at 30mV on ice. The membrane
was then stained with Ponceu S stain (Sigma) to confirm the transfer of the proteins and
to mark the molecular weight markers. The membrane was then blocked with 50 ml of
blocking buffer and shaken for 1 h at room temperature. The membrane was then probed
with P-gp antibody C-219 or with ABCP antibody BXP-21 (Signet Laboratories). The
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primary antibody was diluted to 1:1000 in antibody dilution buffer and allowed to react
with the membrane overnight at 4°C on a shaker. Then next day the membrane was
warmed to room temperature for 30 min prior to washing 4 times with wash buffer (10, 5,
5 and 5 min). A secondary antibody, horseradish peroxidase (HRP) linked sheep antimouse antibody (1:5000, KPL Labs), was applied for 1 h at room temperature. The
membrane was again washed 4 times as earlier and the protein bands were detected using
the enhanced chemiluminescence (ECL) detection reagents (Amersham Pharmacia
Biotech). The two ECL reagents (4 ml each) were mixed and poured over the membrane
for 1 min. The membrane was subsequently sandwiched between 2 transparency sheets
and placed in a Hyperfilm cassette (Amersham Pharmacia Biotech). The X-ray films
were then exposed to the membrane for various time intervals and the film was developed
using an X-ray film developer. The relative amounts of P-gp and ABCP were determined
by density measurements made using Optimas Imaging software (Media Cybernetics,
Silverspring, MD) and reported as optical density (O.D.) values.

Though equal amounts of protein were loaded per lane, the data was normalized
with actin protein to take into account if there were any differences in protein load. The
membranes which were probed for P-gp and ABCP were washed with wash buffer and
stripped using stripping buffer. The stripped membranes were then probed with antiactin antibody (1:200; SantaCruz) followed with (HRP) linked human anti-goat antibody
(1:2000; SantaCruz). The remainder of procedure was followed as outlined above.
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Stocks of sample buffer (NP0007), running buffer (LA0041) and transfer buffer
(NP0006) were purchased from Invitrogen and buffers were prepared according to
manufacturer’s directions. All the buffers were prepared fresh on the day of experiment.
10X TBS: 1 pack of TBS (BupH Tris Buffererd Saline packs (Pierce); 25 mM Tris, 0.15
M sodium chloride, pH 7.2 when pouch contents dissolved in a final volume of 500 ml
dH2O) dissolved in 50 ml of distilled water.
TBS 1X: 2 packs of TBS in 1 liter of distilled water.
Blocking buffer: 5% milk in Tris-buffered saline (TBS)
To 5 ml TBS 10X add 2.5 gm non-fat dry milk and q.s. to 50 ml with distilled water.
Antibody dilution buffer: 1% milk in 0.5% Tween 20 and TBS
To 20 ml of TBS 10X add 2 gm of non-fat dry milk and 0.1 ml of Tween 20 and then q.s.
to 200 ml with distilled water.
Wash buffer: 0.1%Tween 20 in TBS
Add 1 ml Tween 20 to 1 liter of TBS 1X.
Stripping buffer:
Stripping buffer consists of 7 M guanidine HCl, 0.05 mM EDTA, 0.1 M potassium
chloride, 20 mM of β-mercaptoethanol, 50 mM glycine and distilled water to make up the
volume.
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2.9. Preparation of Placental Microsomes
Placental microsomes were prepared according to the methods of Vaz et al. [85]
Briefly, tissues were removed from the -80°C freezer and allowed to thaw on ice in 1%
KCl. All steps were carried out at 4°C (on ice) or in a refrigerated centrifuge. After
removal of the chorionic plate, the tissue was cut into small pieces and washed several
times with 1% KCl to remove excess blood. The tissue was then finely minced using
scissors. To this minced tissue, homogenization buffer was added (4 ml/gm of tissue).
Aliquots of tissue were then disrupted with a Virtishear tissue homogenizer for 1 min and
transferred to a Potter-Elvejehem vessel and homogenized by five passes with a pestle.
The homogenized tissue suspension was then centrifuged in a refrigerated Sorvall RC 5B
(Rotor = SA 600) in 50 ml tubes at 10,000 rpm at 4°C for 20 min. The supernatant was
transferred to clean ultracentrifuge tubes and centrifuged in a Beckman Coulter OptimaTM
LE-80K Ultracentrifuge (Rotor = Ti 70.1) at 100,000 g and 4°C for 60 min. The
supernatant was discarded and wash buffer (same volume as homogenization buffer) was
added to the pellet.

The pellets were resuspended using a glass stirring rod and

centrifuged again for 60 min at 100,000 g as above. The supernatant was discarded and
the pellets were resuspended in storage buffer (1 ml per 5 gm of starting tissue), then
transferred to a 5 ml Potter-Elvejehem tube and homogenized by 3 passes of a pestle.
The suspended microsomes were then aliquoted in labeled microcentrifuge tubes and
stored at -80°C. The protein concentration was determined using BCA protein assay kit
as described earlier.
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KP Stock Buffer (1 M)
K2HPO4
KH2PO4
q.s. to 1 liter with distilled water.

190.71 g
21.78 g

Homogenization Buffer (pH 7.5)
Homogenization buffer consists of 0.15 M KCl and 0.25 M KP buffer
The buffer was made up to volume with distilled water and pH was adjusted to 7.5 with
H3PO4. PMSF(1 mM) was added from 100mM stock in absolute ethanol just before use.

Wash Buffer (pH 7.5)
Wash buffer consists of 0.1 M sodium pyrophosphate and 1 mM EDTA (disodium salt,
dihydrate). The volume was made up with distilled water and pH was adjusted to 7.5.

Microsomal Storage Buffer (pH 7.25)
Microsomal storage buffer consists of 100 mM KP buffer, 1 mM EDTA (disodium salt,
dihydrate), 20% glycerol, 1 mM dithiothreitol and 20 µM butylated hydroxytoluene. The
volume was made up with distilled water and pH was adjusted to 7.25

2.10.

Ethoxyresorufin-O-deethylation Assay for CYP1A1

7-ethoxyresorufin-O-deethylation (EROD) activity catalyzed by CYP1A was
determined in placental microsomes according to the methods of Burke et al. [86] with
slight modifications. Briefly, a 1.25 ml incubation mixture contained Na-K phosphate
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buffer (0.1 M, pH 7.6), 0.5 mg/ml of microsomal protein and 20 µM of 7-ethoxyresorufin
(2 mM stock in DMSO). Following a one minute pre-incubation at 37°C, 1 ml of the
reaction mixture was transferred to a quartz cuvette and autozero was set on the
spectrofluorometer. The reaction was initiated by addition of 1 mM NADPH (freshly
prepared 20 mM stock in water) and the cuvette was inverted to ensure thorough mixing.
Relative fluorescence intensity was measured using a Shimadzu RF-5301 PC
spectroflurometer with excitation and emission wavelengths of 530 nm and 585 nm
respectively. The spectrofluorometer was maintained at 37°C. Relative fluorescence
intensity was measured for 10 min to determine the linear range which was found to be
0.5 min to 3 min at 37°C. The amount of resorufin formed from 7-ethoxyresorufin was
determined using a standard curve for resorufin and activity was calculated from the
equation given below and reported as pmol / min / mg of protein.

 AmountFormedAt 3 min − AmountFormedAt 0.5 min 

pmol / min/ mgofprotein = 
2.5 min× 0.5mgofprotein



Sodium Potassium Phosphate Buffer
Sodium phosphate buffer consists of 0.1 M Na2HPO4, 0.1 M KH2PO4, 2.5 mM MgCl2
and 0.1 M KCl. Make up the volume with distilled water and adjust the pH to 7.6.
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2.11.

Cell Culture

The JAR and BeWo, placental choriocarcinoma cell lines was obtained from
American Type Culture Collection (ATCC). These cell lines were used to study the
induction of placental P-gp after treatment with known inducers of P-gp.

Cell Culture Media – Bewo cell line
To Ham’s F12K media add sodium bicarbonate to get 1.5 g/L and 10% of fetal bovine
serum.

Mix all the above ingredients outside the cell culture hood and then filter

aseptically.
Store at 4°C till use

Cell Culture Media – JAR cell line
RPMI 1640 media with 2 mM L-glutamine was adjusted to contain 1.5 g/L sodium
bicarbonate, 4.5 g/L of glucose and 10 mM of Hepes. To this add 10% of fetal bovine
serum.
Mix all the above ingredients outside the cell culture hood and then filter aseptically. To
this sterile media add the following sterile products aseptically.
1.0 mM of sodium pyruvate, 5 ml of Penicillin / streptomycin solution (10,000 units/ml
of penicillin G sodium and 10,000 µg/ml of streptomycin sulfate in 0.85% saline).
Mix well and store at 4°C till use.

Starting a new culture
The cell culture media was warmed at 37°C. A frozen vial of cells was removed
from the liquid nitrogen freezer and kept on ice. The vial was rapidly thawed at 37°C
(within 2 min) and 1 ml of the cell suspension was transferred to a 75 cm2 cell culture
flask containing 20 ml of warmed cell culture media. The flask was then stored in a
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incubator at 37°C and 5% CO2. The medium was changed every other day and cells were
subcultured every 4-5 days at the ratio of 1:8 for BeWo cells and 1:15 for JAR cells.

Subculturing procedure
Cell culture media, phosphate buffered saline (PBS) and trypsin containing 0.01%
EDTA (aliquoted as 5 ml) were warmed at 37°C. The media from the flask was aspirated
out and cells were washed with 10 ml of PBS twice. After aspirating the PBS, 5 ml of
trypsin was added and the flask was transferred to the incubator for 5 min. After 5 min
the flask was gently tapped to loosen the cells from the surface of the flask. Fifteen ml of
media was added and the cell suspension was pipetted up and down to obtain a single cell
suspension. The cells were then split at the ratio of 1:8 (BeWo cells) or 1:15 (Jar cells)
into a new flask as well as 6 well plates which were used for induction studies.

2.11.1. Induction studies
The cells were plated in 6 well culture plates. At 50 % confluency of cells, the
cells were treated with drugs dissolved in DMSO or appropriate solvent. The JAR cells
were treated with 10 µM rifampin, 10 µM clotriamazole, 0.1, 1, 5, 10 and 25 µM 3methyl cholanthrene (3-MC) dissolved in DMSO or 10 and 50 µM benzo-[a]-pyrene
dissolved in acetone. The cells were also treated with appropriate vehicle controls.
BeWo cells were treated with 10 and 25 µM rifampin and DMSO as solvent control. At
the end of 72 h, the media was aspirated and cells were washed twice with PBS nonaseptically. The cells were then kept on ice and 300 µL of lysis buffer was added. The
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plate was shaken periodically for 10-15 min on ice. With a help of a cell scraper or
rubber policeman, the lysed cells were scraped and transferred to an appropriately labeled
1.5 ml microcentrifuge tube. The cell lysate was then sonicated on ice for 10 sec (x 3)
using a sonicator tip. The cell lysate was aliquoted and stored at -80°C. Protein content
was determined using the BCA assay kit as described earlier. Immunoblotting studies (as
outlined above) were carried out on these cell lysates to determine if P-gp was induced in
these treated cells.

Lysis buffer
Lysis buffer consists of 50 mM Tris-HCl, pH 7.0, 1.0% Triton X-100, 1 mM PMSF (100
mM stock in absolute ethanol), 10 µg/ml leupeptin and 20 µg/ml aprotinin.
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CHAPTER – III
3. EVALUATION OF P-GLYCOPROTEIN AND ABCP
EXPRESSION AND FUNCTION IN HUMAN
PLACENTAL TISSUE FROM SMOKERS AND
NON-SMOKERS
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3.1. Introduction

P-glycoprotein (P-gp), encoded by the ABCB1 (MDR1; multidrug resistance)
gene, is an efflux transporter that pumps xenobiotics out of cells, utilizing ATP as the
energy source. P-gp is present in various normal tissues [9] like intestine, liver and
kidney where it plays an important role in absorption, distribution and excretion of drugs
[87]. In addition, P-gp also plays a role in the transport of xenobiotics across the blood
brain barrier, modulating their CNS effects [88]. Another tissue in which P-gp regulates
xenobiotic transfer is the placenta. Studies in mdr knock-out mice have demonstrated that
placental P-gp can affect the transfer of xenobiotics across the placental barrier [10;13],
suggestive of a role in protecting the fetus from drugs ingested by the mother during
pregnancy or environmental toxicants.
Polycyclic aromatic hydrocarbons (PAH) are primary constituents of cigarette
smoke and can be classified as environmental toxicants. Cigarette smoking has been
associated with adverse outcomes during pregnancy including changes in function and
structure of the placenta.

Furthermore, maternal smoking has been associated with

increased fetal morbidity and mortality. Smoking and the associated PAHs can affect
drug metabolizing enzymes and increase levels of cytochrome P450 1A1 (CYP1A1) in
human placenta [62].

However, the effect of smoking on drug efflux transporters

expressed in placenta is not known. In-vitro studies using rat [76], mouse [77] and
human hepatocytes [17], have demonstrated that P-gp mRNA was induced by 3methlycholanthrene (3-MC), a PAH. In addition, the PAH benzo[a]pyrene, which is a
substrate of CYP1A1, is also transported by P-gp [78]. Thus, analogous to CYP1A1
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induction, there could possibly be induction of P-gp in placentas of women who smoke
during pregnancy. Based on these lines of evidence, we hypothesized that smoking might
increase P-gp levels in human placenta.
In addition, we also studied the expression and function of ABCP which is a
recently discovered protein belonging to the ABC superfamily of proteins. ABCP [36],
also known as MXR [38] or BCRP [37], is a 70 kDa protein encoded by ABCG2 and is
also involved in the active efflux of drugs. It is expressed at high levels in placenta, liver
and small intestine and lower expression is seen in kidney, heart and brain [38;49].
Studies in mdr knock-out mice have shown that there was increased placental transfer of
topotecan in mdr knock-out mice in the presence of GF120918, an ABCP inhibitor, as
compared to without GF120918 [51]. This suggests a protective role of ABCP, similar to
P-gp, in the placenta.
To study the effect of smoking on function and expression of both these proteins,
placentas were collected from smokers and non-smokers and membrane vesicles isolated.
In addition, since CYP1A1 activity is induced by smoking [62], CYP1A1 activity was
also measured in human placental microsomes as a positive control for the effect of
smoking.
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3.2. Methods

Materials. [3H]-vinblastine (10.9 Ci/mmol) and [3H]-mitoxantrone (3 Ci/mmol)
were purchased from Amersham Biosciences (Piscataway, NJ) and American
Radiolabeled Chemicals (St. Louis, MO) respectively.

Verapamil, mitoxantrone,

vinblastine, resorufin, 7-ethoxyresorufin, ATP, creatine phosphokinase, NADPH, EGTA,
PMSF and bovine serum albumin were purchased from Sigma Chemical Co. (St. Louis,
MO). Creatine phosphate was purchased from Fluka (Switzerland). Scintiverse ® BD,
magnesium chloride and EDTA were purchased from Fisher Co. (Pittsburgh, PA).
Fumitremorgin C (FTC) was a gift from Dr. Susan Bates (NIH). All other chemicals
were purchased from commercial sources and were of the highest purity available.

Tissue Collection.

Human placental tissue was obtained under a protocol

approved by the West Virginia University Institutional Review Board for the Protection
of Human Research Subjects. Placentas were obtained from ten smokers and ten nonsmokers who had given written informed consent prior to obstetric delivery. Smoking
status was assessed by patient interview.

Placentas were collected and processed

immediately after delivery. Two triangular wedges extending from center of the placenta
to the placental margin were cut. One piece was frozen at -80°C for later preparation of
microsomes and the other piece was immediately processed to prepare the membrane
vesicles.
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Preparation of Microvillus Membrane Vesicles.

Microvillous membrane

vesicles (MVM) were prepared according to the methods of Illsley et al. [79]. Briefly,
the tissue was cut and washed in 0.9% NaCl. The washed tissue was further minced
finely and suspended in 3 volumes of buffer containing 10 mM Tris-Hepes (pH 7.0), 250
mM sucrose, 5 mM EGTA, 5 mM EDTA and 1 mM PMSF (buffer 1). This suspension
was homogenized for 2 min and centrifuged at 10,000 g for 15 min. The supernatant was
collected and centrifuged at 47,500 g for 1 h. The pellet was resuspended in buffer 1 and
MgCl2 was added (12 mM final concentration). The mixture was stirred on ice for 20
min and centrifuged at 2500 g for 15 min. The supernatant was again centrifuged at
47,500 g for 30 min to get the MVM pellet. This pellet was washed and resuspended in
buffer 2 (10 mM Tris-HCl (pH 7.4) and 250 mM sucrose) using a 25-gauge needle
through which the suspension was passed ten times. The vesicles were aliqouted and
stored at –80°C. Protein concentration was determined by the BCA assay kit (Pierce).
The percentage of inside-out vesicles was determined by sialidase accessibility [81] [82]
and membrane vesicles were found to be 18-20% inside-out.

Uptake by Membrane Vesicles. ATP dependent transport of the radiolabeled
substrate into membrane vesicles was measured by filtration using a 12 channel sampling
manifold (Millipore. Corp., Bedford, MA). Transport buffer (45 µL) containing 10 mM
Tris-HCl pH 7.4, 250 mM sucrose, 10 mM MgCl2, 20 nM [3H]-vinblastine (5000 cpm) or
50 nM [3H]-mitoxantrone (1300 cpm) and enough amount of respective unlabeled drug to
produce a final concentration of 100 nM and an ATP regenerating system consisting of
10 mM phosphocreatine and 100 µg/ml creatine kinase were warmed at 37°C before
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initiating the reaction. Reactions were carried out in the presence or absence of 4 mM
ATP. The reaction was initiated by addition of 10 µL of vesicle aliqout (25 µg of
protein) and quenched after 10 min (vinblastine) or 6 min (mitoxantrone) with the
addition of 3 ml of ice-cold stop solution (10 mM Tris-HCl pH 7.4 and 250 mM sucrose).
The quenched reaction mixture was filtered immediately through nitrocellulose filters
(0.45 µm Whatman) presoaked in 3% BSA, and washed with an additional 3 ml of icecold stop solution under light suction. The filters were then placed in a scintillation vial,
Scintiverse® BD scintillant added, and radioactivity measured by liquid scintillation
counting.

ATP dependent uptake of radiolabeled substrate was calculated as the

difference in the uptake of substrate measured in the presence and absence of ATP and
reported as pmol / mg of protein.

Immunoblotting for P-gp and ABCP. Membrane vesicle protein (10 µg) was
heated at 90°C for 10 min then loaded onto 7% Tris-acetate mini-gels (Invitrogen) and
electrophoresed. The proteins were then transferred to a nitrocellulose membrane after
which the membrane was blocked in blocking buffer (5% non-fat dry milk in Tris
buffered saline) for 1 h at room temperature and then incubated with C-219 P-gp
antibody or BXP-21 ABCP antibody (1:1000, Signet Laboratories) overnight at 4°C. The
membrane was then washed with Tris buffered saline containing 0.1% Tween 20 (TTBS)
and incubated with horseradish peroxidase linked sheep antimouse antibody (1:5000,
KPL Labs) for 1 h at room temperature. After washing with TTBS, the blots were
developed with an enhanced chemiluminescence detection system (Amersham Pharmacia
Biotech).

The relative amounts of P-gp and ABCP were determined by density
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measurements made using Optimas Imaging software (Media Cybernetics, Silverspring,
MD) and reported as optical density (O.D.) values.

Measurement of CYP1A1 activity.

Placental microsomes were prepared

according to established methods [85]. Ethoxyresorufin-O-deethylation (EROD) activity
catalyzed by CYP1A1 was determined as described by Burke et al. [86] with slight
modifications. Briefly, 0.5 mg/ml of microsomal protein was incubated with 20 µM of 7ethoxyresorufin (2 mM stock in DMSO) and Na-K phosphate buffer (0.1 M, pH 7.6) in a
total volume of 1.25 ml at 37°C for 1 min.

One ml of the reaction mixture was

transferred to a cuvette and the reaction was initiated by addition of 1 mM NADPH.
Relative fluorescence intensity was monitored for 4 min using a Shimadzu RF-5301PC
spectroflurometer at 37°C and set at excitation and emission wavelengths of 530 nm and
585 nm, respectively. The rate of formation of resorufin from 7-ethoxyresorufin was
calculated from a standard curve for resorufin and activity reported as pmol / min / mg of
protein.

Statistical Analysis.

Statistical comparisons of P-gp, ABCP and CYP1A1

activity as well as P-gp and ABCP expression between smokers and non-smokers were
made using a one sided t test. Statistical significance was set at p<0.05.
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3.3. Results

P-gp and ABCP expression in human placenta. A 170 kDa P-gp protein was
detected in all 20 samples of human placenta. However, substantial inter-individual
variability in P-gp expression among the samples was noted (Figure 3.1). Statistical
analysis showed that P-gp protein abundance was comparable between smokers and nonsmokers (Table 3.1). Similarly, an ABCP protein band was detected at 70 kDa, as
reported by others, and its expression also was comparable between smokers and nonsmokers (Table 3.1).

Uptake of [3H]-vinblastine in membrane vesicles (P-gp activity).

ATP

dependent transport of [3H]-vinblastine was observed in membrane vesicles isolated from
human placenta. This transport was also time dependent (data not shown). To determine
whether the transport was truly intravesicular or just due to increased binding to P-gp in
the presence of ATP, the effect of osmolarity on the transport of vinblastine by P-gp was
studied. Figure 3.2 demonstrates that the transport observed was intravesicular as the
uptake decreased with decreasing intravesicular volume resulting from increased
osmolarity.
To determine if the vinblastine uptake was mediated by P-gp, uptake studies were
carried out in the presence of verapamil, a known inhibitor of P-gp. ATP dependent
vinblastine uptake was inhibited 42 % by 10 µM and 71% by 100 µM verapamil (Figure
3.3), confirming the involvement of P-gp in vinblastine uptake.
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Table 3-1 Expression of P-gp and ABCP in placental vesicles
Optical density values (mean ± S.D.) for P-gp and ABCP protein abundance in human
placental tissue from smokers and non-smokers.
Densitometric analysis

Smokers

Non-smokers

(O.D.)

(n = 10)

(n = 10)

P-gp expression

4.26 ± 1.30

3.88 ± 2.28

ABCP expression

3.79 ± 1.71

2.81 ± 1.04

O.D. = optical density
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Figure 3-1 Representative immunoblot of P-gp in placental vesicles
Lanes 1, 3, 9, 11 and 12 are samples from smokers and lanes 2, 4, 5, 6, 7, 8 and 10 are
samples from non-smokers.
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Uptake of [3H]-vinblastine
(pmol / mg of protein)
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Figure 3-2 Effect of osmolarity on ATP dependent uptake of [3H]-vinblastine in
microvillus membrane vesicles.
Placental vesicles (25 µg) were incubated for 10 min with [3H]-vinblastine in the
presence or absence of ATP (4 mM) in transport buffer containing increasing
concentrations of sucrose (250, 333, 500 and 1000 mM). Data represent the difference
between the ATP dependent and independent uptake determined in triplicate samples.
The coefficient of variation was less than 15% for each triplicate determination.

58

Uptake of [3H]-vinblastine
(pmol / mg of protein)
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Figure 3-3 Effect of verapamil on ATP dependent uptake of vinblastine in
microvillus membrane vesicles
Data represents the ATP dependent transport of vinblastine in absence (control) and
presence of verapamil (VER 10 µM and VER 100 µM). Mean of triplicate
determinations with coefficient of variation less than 15% for all sets.
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P-gp expression Vs P-gp activity
Regression with all data points
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Figure 3-4 Correlation of P-gp activity with P-gp expression
On correlating P-gp activity with P-gp expression a positive correlation was seen with an
r2 = 0.45.
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Placental P-gp activity, measured as the uptake of vinblastine, was not statistically
different (p>0.05) in smokers and non-smokers (Table 3.2).

With respect to the

correlation of P-gp expression and activity, a positive correlation, r2 = 0.45 was obtained
(Figure 3.4).

Uptake of [3H]-mitoxantrone in membrane vesicles (ABCP activity). ATP
dependent transport of mitoxantrone was observed in membrane vesicles. To determine
if this transport was mediated by ABCP, mitoxantrone uptake was measured in the
presence of fumitremorgin C, a selective inhibitor of ABCP as well as verapamil, an
inhibitor of P-gp. In the presence of 10 µM fumitremorgin C, a 65% inhibition of ATP
dependent mitoxantrone transport was observed whereas 10 µM verapamil had minimal
effect (Figure 3.5). Placental ABCP activity, measured as the uptake of mitoxantrone,
was not statistically different (p>0.05) between smokers and non-smokers (Table 3.2).
With respect to the correlation of ABCP expression and activity, a positive correlation, r2
= 0.25 was obtained (Figure 3.6). However, on exclusion of one data point as an outlier a
better correlation with r2 = 0.74 (Figure 3.6) was obtained.
ABCP is a half transporter and is thought to require dimerization to be active [89].
It has been demonstrated that in the absence of reducing agent, ABCP migrates as 140
kDa protein on electrophoretic gels [39]. We observed similar results on blots where
ABCP migrated as a 140 kDa protein under non-reducing conditions (in the absence of
dithiothreitol, DTT) and as a 70 kDa protein under reducing conditions (in the presence
of DTT) (Figure 3.7). This suggests that ABCP exists as a dimer in non-reducing
conditions and as a monomer under reducing conditions. In addition, we were also able
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to demonstrate for the first time that there was decreased transport of mitoxantrone by
ABCP in presence of 1 mM DTT as compared to without DTT (Figure 3.8). Thus, in
presence of DTT, ABCP appears to be present as a monomer and loses its ability to
transport substrates.

These results taken together confirm that ABCP requires

dimerization to be functional.

Ethoxyresorufin O-deethylation (EROD) in placental microsomes (CYP1A1
activity). As a positive control for the effects of smoking, we measured CYP1A1
function using the EROD assay. CYP1A1 activity was highly induced in smokers,
however, we were only able to measure this activity in 2 out of 10 microsomal samples
prepared from placentas of non-smokers. Table 3.2 shows the activity seen in each group
and the range of values obtained.

62

3
Uptake of [ H]-mitoxantrone
(% of the control)

120
ATP dependent uptake

100
80
60
40
20
0
Control

+ FTC (10 µM)

+ VER (10 µM)

Figure 3-5 Effect of an ABCP inhibitor (FTC) and a P-gp inhibitor (VER) on the
uptake of mitoxantrone in microvillus membrane vesicles
Data represent ATP dependent uptake of mitoxantrone. Fumitremorgin C (FTC)
inhibited mitoxantrone uptake by 65 % whereas verapamil (VER) had minimal effect on
mitoxantrone transport suggesting that mitoxantrone transport is predominantly mediated
by ABCP. Mean of triplicate determinations with coefficient of variation less than 15%
for all sets.

63

Table 3-2 Functional activity of P-gp, ABCP and CYP1A1
Functional activity (mean ± SD) of P-gp and ABCP measured as uptake of vinblastine
and mitoxantrone, respectively, in microvillus membrane vesicles. CYP1A1 activity
(mean ± SD) measured as ethoxyresorufin -O-deethylation in placental microsomes.
Smokers

Non-smokers

(n = 10)

(n = 10)

2.25 ± 1.12

1.72 ± 0.67

6.25 ± 1.55

5.53 ± 2.09

Parameter (units)
P-gp mediated vesicular uptake of vinblastine
(pmol / mg of protein)
ABCP mediated vesicular uptake of mitoxantrone
(pmol / mg of protein)
CYP1A1 activity in placental microsomes

0.56
3.61 ± 2.96

(pmol / min / mg of protein)

(0.19 , 0.93) *

* Measurable values, 8 of the 10 samples were below the limit of detection.
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Figure 3-6 Correlation of ABCP activity with ABCP expression
The dashed line represents the regression line with all the data points and has a r2 = 0.25
whereas the solid line represents the regression line with all the data points except one
which is shown in a box and has a r2 = 0.74.
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Figure 3-7 Immunoblot expression of ABCP in the presence and absence of
reducing conditions
Electrophoresis was carried out under reducing conditions [presence of 1 mM DTT] (lane
1, 3 and 5) and under non-reducing conditions [absence of 1 mM DTT] (lane 2, 4 and 6).
Band at 140 kDa is suggestive of the presence of a dimeric form of ABCP whereas the
band at 70 kDa is suggestive of a monomeric form.
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Uptake of [3H]-mitoxantrone
(pmol / mg of protein)
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+ 1mM DTT
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Figure 3-8 Effect of 1 mM dithiothreitol (DTT) on ATP dependent uptake of
mitoxantrone by ABCP in placental vesicles from two subjects (PT-20 and PT-22)
Uptake of [3H]-mitoxantrone in placental vesicles (25 µg) in the absence (dark bars) and
presence (light bars) of 1 mM DTT. Each bar represents the difference in uptake in
presence and absence of ATP (4 mM) carried out in triplicate and coefficient of variation
was less than 15% for all sets.
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3.4. Discussion
PAHs, which are the principal constituents of cigarette smoke, have been shown
to induce drug-metabolizing enzymes such as CYP1A1 in human placenta. It has been
reported that PAHs such as 3-MC can induce the levels of P-gp mRNA in rat [76], mouse
[77] and human hepatocytes [17]. However, the effect of smoking on placental drug
efflux transporters, such as P-gp and ABCP, is not known. To this end, we studied the
function and expression of placental P-gp and ABCP and their regulation by smoking in
placentas from smokers and non-smokers.
Vinblastine was used as a model substrate of P-gp function in placental vesicles.
To confirm that measured radioactivity on the filters was due to intravesicular transport
and not just increased binding to vesicles, experiments in which increasing concentrations
of sucrose were added to the transport buffer were conducted (Figure 3.2). Increased
osmolarity of the medium should decrease the intravesicular volume and lead to
decreased uptake in vesicles if intravesicular transport is occurring [84]. As seen in
Figure 3.2, the uptake of vinblastine decreased as the osmolarity of the transport buffer
increased, demonstrating that the observed ATP dependent transport was at least partly
intravesicular and not due to increased binding of vinblastine to P-gp.

Additional

confirmation of the involvement of P-gp in this active transport process was obtained by
using verapamil, an established inhibitor of P-gp.

Verapamil 10 µM and 100 µM

inhibited ATP dependent vinblastine uptake by 42% and 71%, respectively (Figure 3.3).
That the process was osmotically sensitive and inhibited by a known P-gp inhibitor
strongly suggests that the ATP dependent transport of vinblastine was intravesicular and
carried out by P-gp.
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In addition to P-gp, ABCP also has been reported to be present at the apical
surface of placenta. To the best of our knowledge, there are no reports of functional
studies of ABCP in human placenta. Mitoxantrone, a known substrate for ABCP, was
used to measure ABCP function in the microvillus membrane vesicles. To verify the
involvement of ABCP in mitoxantrone transport, uptake experiments were performed in
the presence of fumitremorgin C (10 µM), a selective inhibitor of ABCP [44], and
verapamil (10 µM), a P-gp inhibitor. As shown in Figure 3.4, fumitremorgin C inhibited
mitoxantrone uptake by 65 % whereas verapamil exhibited minimal effect.

Since

verapamil exhibited a minimal effect on mitoxantrone uptake, suggests that the uptake of
mitoxantrone was primarily mediated by ABCP and not by P-gp.
ABCP is a half transporter and has 6 transmembrane domains and only one ATP
binding site, unlike P-gp which is a full transporter and has twelve transmembrane
domains and two ATP binding sites [14]. As ABCP is a half transporter, it is assumed to
require dimerization to be a functional protein [89]. In its monomeric form, ABCP
migrates as a 70 kDa protein. However, under non-reducing conditions ABCP migrates
as a 140 kDa protein, suggesting it forms a dimer [39]. To confirm this dimerization,
placental vesicle samples were electrophoresed under reducing (in the presence of DTT)
and non-reducing conditions (in the absence of DTT) (Figure 3.5). Under the nonreducing conditions a large band was observed at 140 kDa, whereas this band was
completely absent when samples were electrophoresed under reducing conditions,
wherein it migrated as a 70 kDa protein. The minimal expression of 70 kDa protein seen
under non-reducing conditions could be due to some ABCP monomers that had not
dimerized. To confirm that dimerization of ABCP is necessary for functionality, we
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performed mitoxantrone uptake studies in the presence and absence of 1 mM DTT
(Figure 3.6). As DTT is a reducing agent, it should cleave the dimer and thus decrease
the functional activity of ABCP. An approximately 65% reduction in mitoxantrone
uptake was noted in the presence of DTT as compared to the absence of DTT. These
results suggest that ABCP dimerization is required for functionality. Since no dimer was
detected in the immunoblotting studies in the presence of DTT (reducing conditions), the
small amount of mitoxantrone transport noted in the presence of 1 mM DTT was most
likely due to the binding of mitoxantrone to ABCP in presence of ATP.
Though substantial expression of P-gp and ABCP protein in placental vesicles
was noted, no statistical differences were noted in expression levels between smokers and
non-smokers (Table 3.1). Likewise, no statistical difference was noted in P-gp and ABCP
functional activity between these two groups (Table 3.2), however, statistical power was
low. To achieve a power of 0.8 at p<0.05, it was calculated that a sample size of 26
subjects per group would be required to meet these statistical levels for ABCP expression
and substantially higher numbers of samples for P-gp expression and activity and for
ABCP activity.
As mentioned above, substantial inter-individual variability was seen in the
expression and activity of P-gp and ABCP in human placental samples (Table 3.1 and
3.2). Induction of the ABCB1 gene by 3-MC and TCDD in human hepatocytes has been
reported by Schuetz et al. [17]. Primary human hepatocytes from 15 individuals were
treated with 3-MC and TCDD, from which only 62% and 55%, respectively, of the
primary hepatocyte cultures showed induction of the ABCB1 gene, suggesting that this
inducibility was polymorphic [17]. Genotyping studies have reported a SNP at C3435T
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in exon 26 and subjects having the T/T allele exhibited much lower expression and
activity of P-gp measured in-vivo, suggesting a correlation between the genotype and
phenotype [33;34]. However, other researchers have reported that individuals with the
T/T allele exhibit higher expression of P-gp and thus higher activity [35]. Thus, the
effects of genetic polymorphisms with respect to the direction of change in P-gp
expression and activity are still unclear. These types of polymorphisms may in part,
explain the substantial inter-individual variability in P-gp expression and activity noted in
the present study. Mutations in the amino acid at position 482 in ABCP overexpressing
cells lines have also been reported, resulting in an alteration in substrate specificity of
ABCP. The wild type ABCP has arginine at position 482, which is replaced by threonine
or glycine in mutated cells [43;53]. Whether these mutations exist in normal human
tissues and change the expression and function of ABCP is not yet known. To this end,
we have begun studies to genotype the samples used in our study for correlation of
genotype, phenotype and smoking status for both P-gp and ABCP.
To assure that maternal smoking was resulting in alterations in placental
biochemical processes, measurement of CYP1A1 activity in placental microsomes was
used as a positive control. CYP1A1 activity was substantially greater in smokers as
compared to non-smokers (Table 3.2). Since smoking induced CYP1A1 activity but not
P-gp or ABCP activity, the lack of effect appears not to be due to insufficient smoking
activity necessary to induce biochemical processes such as P-gp or ABCP activity.
In conclusion, we were able to measure P-gp and ABCP expression and activity in
placental membrane vesicles. This constitutes the first report of functional studies on
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ABCP in human placenta. However, it appears that smoking does not induce P-gp or
ABCP activity or expression in human placenta.
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CHAPTER – IV
4. INDUCTION OF P-GLYCOPROTEIN AND CYP3A
ACTIVITIES IN LS174T CELLS
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P-gp can affect drug bioavailability as it plays a role in absorption, distribution
and elimination.

Induction of P-gp leads to decreased absorption and increased

elimination of drug substances and can play a role in drug-drug interactions. Such
interactions become extremely important for drugs that are P-gp substrates and have
narrow therapeutic indices. Our laboratory was interested in studying the induction of Pgp by various xenobiotics. At the same time, I was offered an opportunity to do a
summer internship at Pharmacia Corp., Kalamazoo, MI, under the direction of Dr. Joseph
Ware. As a part of my summer internship, I worked on a project to evaluate LS174T
cells as a model cell line to study the induction of P-gp and CYP3A4 simultaneously.
P-gp and CYP3A4 have a number of overlapping substrates and are co-localized
in various tissues such as intestine, liver and kidney. Common substrates are pumped
back into the gut lumen by P-gp and metabolized by intestinal CYP3A4; thus, P-gp and
CYP3A4 act additively to decrease the oral bioavailability of several xenobiotics. In
addition, both proteins are known to be coordinately upregulated.

To this end,

development of a common system for studying both P-gp and CYP3A4 induction
simultaneously could prove beneficial to the drug discovery process.
LS174T, a colon carcinoma cell line, has been used as an intestinal model. It has
been shown that in these cells the ABCB1 gene is inducible by rifampin. There are
reports of increased expression of P-gp in these cells, however, whether CYP3A4 is also
induced in these cells has not been studied. Given that both of these proteins have
common inducers and are induced in intestinal tissue, the LS174T cell line seemed ideal
for studying the simultaneous induction of P-gp and CYP3A4.
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The pregnane X-receptor (PXR) is a nuclear hormone receptor and is a key
regulator of CYP3A4 induction. Recently, its involvement in the regulation of the
ABCB1 gene has also been noted. PXR binding element is present in the upstream region
of ABCB1 gene in LS174T cells. At Pharmacia, Dr. Rich Voorman and Evan Smith use a
reporter gene assay to screen compounds for their ability to activate PXR. Since PXR is
identified as a key regulator in the induction of P-gp and CYP3A4, the reporter gene
assay results can be used for prediction of induction of P-gp and CYP3A4. Our second
purpose was to determine how data from the PXR reporter gene assay would correlate
with results from induction studies in LS174T cells. Thus a collaboration with Dr. Rich
Voorman and Evan Smith was formed to evaluate the correlation of these results.
Compounds which were poor, intermediate and strong activators of PXR were selected
and their ability to induce P-gp in LS174T cells was compared and correlated to their
ability to activate PXR in a reporter gene assay.
The following chapter describes the experimental procedures used in these
studies, their results and a discussion of the findings. I would like to thank Dr. Rich
Voorman and Evan Smith for sharing the PXR reporter gene assay data that is presented
in the next chapter with me.
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4.1. Introduction

Prediction of drug-drug interactions early in the development of new drugs is
beneficial in the process of drug discovery. Induction of drug metabolizing enzymes and
transporters that govern the absorption, distribution, metabolism and excretion of drugs is
one cause of drug-drug interactions [22;90].
The ABCB1 (MDR1) gene encodes for P-glycoprotein (P-gp), an ATP dependent
integral transmembrane protein which acts as an efflux transporter. It pumps xenobiotics
out of cells and decreases their intracellular concentrations [4]. It is expressed in various
tissues including intestine, liver, kidney, brain and placenta [87] wherein it plays a role in
absorption, distribution and excretion of xenobiotics.
Cytochrome P450 3A4 (CYP3A4) is an important drug metabolizing enzyme
constituting about 70% of intestinal and 30% of the hepatic P450 metabolizing enzymes
present. It is responsible for metabolism of more than half of the drugs on the market
[91;92]. Induction by a variety of chemicals augments the metabolism and clearance of
co-administered drugs which are CYP3A4 substrates and can lead to alteration of their
therapeutic efficacy [93;94]. Because of this, it is desirable to screen compounds for their
ability to induce CYP3A.
P-gp has broad substrate specificity with many compounds also being CYP3A4
substrates [16]. Both proteins are expressed in several common tissues [95] and can
additively affect the bioavailability of certain drugs [96;97]. Moreover, it has also been
shown that both proteins are coordinately upregulated in colon carcinoma cells when
exposed to common inducing agents [16].
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Therefore, in addition to screening for

inducibility of CYP3A, compounds should also be screened for their ability to induce Pgp. In addition, the functional activity of these induced proteins is critical.
Induction of CYP3A by different agents has been studied in animals [18],
hepatocytes [98;99] and cell lines [16].

However, only recently has the molecular

mechanism of induction been known. Pregnane xenobiotic receptor (PXR), a nuclear
hormone receptor, has been found to be responsible for drug induced expression of
CYP3A4 [100;101]. PXR has also been implicated in the induction of P-gp [24]. A PXR
response element to which PXR can bind was found in the 5’ upstream region of the
ABCB1 gene [27]. As CYP3A4 and P-gp both depend on PXR for the control of
expression, it is important to assess whether induction by various agents is common to
each protein as well. The colon carcinoma cell line LS174T has been shown to possess
the ABCB1 gene which can be induced [27]. In the present work, this cell line was used
to develop a model for simultaneous assessment of drug candidates for their ability to
induce P-gp and CYP3A4 activity. To further support the involvement of PXR in
induction of ABCB1, the ability of various drugs to activate PXR was compared and
correlated with their ability to induce P-gp.
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4.2. Methods

Materials.
(Piscataway, NJ).

[3H]-vinblastine was purchased from Amersham Biosciences,
Cyclosporin A was purchased from Fluka (Switzerland).

The

chemicals with PNU number were synthesized by Pharmacia Corp. (Kalamazoo, MI).
All other chemicals were purchased from commercial sources and were of the highest
purity available.

Cell Culture. The colon carcinoma cell line LS174T was obtained from the
American Type Culture Collection. The cells were maintained in Minimum Essential
Media supplemented with 10% fetal bovine serum, 0.1mM nonessential amino acids,
sodium pyruvate and glutamine (Invitrogen). The medium was changed every 3 days and
the cells were subcultured at the ratio of 1:3 to 1:5. In a 6 well culture plate at 50%
confluence, cells were treated with drugs dissolved in DMSO (0.1% final concentration).
0.1% DMSO was used as solvent control in cells not treated with drugs. Treatment with
drugs was continued for 72 hours or the indicated time, after which the cells were washed
twice with phosphate buffered saline and then lysed with lysis buffer (50mM Tris, pH
7.0, 1.0% Triton X-100, 1 Protease Minitab (Boehringer Ingelheim) /10mL). The cell
lysate was stored at -80°C. Protein content was determined using the BCA protein assay
kit (Pierce).

Western Blot Analysis. Cell lysates (10µg) were loaded on 7% Tris-acetate
mini-gels (Invitrogen) and electrophoresed.
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The proteins were transferred to a

nitrocellulose membrane and stained with Ponceu S solution (Sigma) to confirm transfer.
The membrane was blocked in blocking buffer (5% non-fat dry milk in Tris buffered
saline) for 1 h at room temperature and then incubated with C-219 P-gp antibody
(1:1000, Signet laboratories) overnight at 4°C. The membrane was then washed with
Tris buffered saline containing 0.1% Tween 20 (TTBS) and incubated with horseradish
peroxidase linked sheep antimouse antibody (1:5000, KPL laborartories) for 1 h at room
temperature.

After washing with TTBS, the blots were developed with enhanced

chemiluminescence detection system (Amersham Pharmacia Biotech).

The relative

amounts of P-gp were determined by densitometric analysis after scanning the blot using
a Bio-Rad densitometer.

Flow Cytometry. Cell suspensions (100 µl) at 1-2 x 106 cells/ml were incubated
with either control (γ2a, Becton Dickinson) or anti-P-gp (MRK-16, Kayima Biomedical
Co.) monoclonal antibodies (20 µl at 50 µg/ml) for 1 h at room temperature. After
centrifugation and removal of supernate, fluorescent-goat anti-mouse IgG (100 µl at 1/50
dilution) was added and incubated for 45 min at room temperature, followed by
centrifugation and resuspension in 200 µl sheath buffer (Becton Dickinson). Samples
were analyzed in a FACScan (Becton Dickinson) flow cytometer by gating on cells using
forward (FSC) and side (SSC) scatter parameters and measuring fluorescence at 530 nm
(FL1 channel).

Uptake of [3H]-Vinblastine. Cells were grown at high density in 24 well plates
with 12 wells treated with 10 µM rifampin and the other 12 wells with 0.1% DMSO
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solvent control. At the end of 72 h the cells were washed twice with PBS at 37°C with
mixing.

The control wells and rifampin treated wells were pretreated with 5 µM

cyclosporin A (n = 6) and vehicle (n = 6) for 30 min at 37°C. [3H]-vinblastine (0.25
µCi/mL) was added and incubated for 1 h at 37°C with mixing. At the end of 1 h the
remaining solution was aspirated and the cells were rinsed twice with ice-cold PBS. The
cells were then dissolved in Solvable TM for 30 min at 37°C and transferred to a
scintillation vial to measure the amount of cell associated radioactivity.

Measurement of 1’-hydroxy midazolam. The LS174T cells were washed twice
with PBS and then incubated with 10 µM midazolam at 37°C for 1 h on a slow shaker.
At the end of 1 h the reaction was stopped with quenching solution (5 µg/ml of
carbamazepine (internal standard) in methanol and 3% formic acid). The contents of
each well were transferred to tubes and centrifuged (14000 rpm). The supernate was
analyzed for 1’-hydroxy midazolam using LC-MS analysis. LC/MS was performed in
positive ion scan mode on a Finnigan-MAT TSQ 7000, and by gradient reverse-phase
chromatography (0.1% formic acid 95% to 0% in ACN over 20 min) on a Zorbax C18,
150 x 2.1 mM i.d. reverse-phase column (0.3 ml/min). Extracted ion chromatograms of
carbamazepine (MH+ m/z 237) and hydroxy-midazolam (MH+ m/z 342) were obtained
and used to determine peak area ratios (metabolite-of-interest / carbamazepine).

PXR reporter gene assay: HUH7 cells, maintained in RPMI Medium 1640
(Invitrogen Corporation, Carlsbad, CA) supplemented with 10% heat-inactivated FBS
(Invitrogen), 100 units/mL penicillin G (Invitrogen) and 100 µg/mL streptomycin sulfate
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(Invitrogen), were plated at a density of 50,000 cells/cm2 growth surface area in 150 mm
x 25 mm tissue culture dishes. After eight hours, cells were transfected with 5.8 µg/dish
of receptor expression plasmid and 23.4 µg/dish of reporter plasmid using Lipofectamine
2000 (Invitrogen) essentially according to the manufacturer’s instructions.

Eighteen

hours after transfection, cells were detached and diluted to 50,000 cells/mL with reduced
serum medium (RPMI Medium 1640 supplemented with 1% FBS). The diluted cell
suspension was added to 96-well assay plates (200 µL/well) containing 1 µL samples of
test compounds dissolved in DMSO.

Cells were incubated in the presence of test

compounds for 24 hours before detection of luciferase activity using Sleady-Glo
luciferase detection reagent (Promega).

Fold induction values were calculated by

dividing the luminescence response for the test well of a given compound with the
average luminescence response of the four DMSO control wells on the same plate.

Statistical Analysis. Unistat® version 5.0 was used for comparison of the two
groups.

Correlations between groups were measured by Pearson’s correlation

comparisons and statistical significance was set at p<0.05.
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4.3. Results

P-gp expression and function in LS174T cells.

Rifampin, a prototypical

inducer of P-gp expression was used to characterize the induction of P-gp expression in
LS174T cells. Immmunoblotting results demonstrated that induction by rifampin was
dose (Figure 4.1) and time dependent (data not shown). Based on these results, a dose of
10 µM and 72 h time exposure were used in all further experiments. In addition to
rifampin, reserpine also induced P-gp expression (data not shown). To determine the
surface expression of P-gp in LS174T cells, flow cytometry measurements were carried
out using MRK-16 anti P-gp antibody that recognizes the external epitope of P-gp.
Vehicle (DMSO) and rifampin / reserpine treated cells were analyzed for their binding to
control and MRK –16 antibody. The fluroscence intensity was 3.5 and 4.0 fold higher in
rifampin and reserpine treated cells respectively as compared to vehicle control treated
cells (Figure 4.2). This suggests that the induced protein is present at the cell surface of
the cells. To determine if the induced protein was functionally active, cellular uptake of
[3H]-vinblastine was measured in the presence and absence of cyclosporin A (CsA, 5
µM). As seen in Figure 4.3, [3H]-vinblastine uptake was significantly lower (p<0.05) in
rifampin treated cells as compared to vehicle control cells. Uptake in the CsA treated
control cells was significantly higher (p<0.05) than in control cells without CsA
suggesting that baseline P-gp activity was inhibited by CsA. Uptake of [3H]-vinblastine
in rifampin treated cells also was higher in the presence of CsA than in the absence of
CsA, however, this increase was not statistically significant.
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Figure 4-1 Dose dependent induction of immunoreactive P-glycoprotein after
rifampin treatment
Cells at 50% confluency were treated with vehicle (DMSO) or 0.1, 1, 5, 10 and 25 µM of
rifampin for 72 hrs. At the end of 72 hrs the cell lysate was analyzed for P-gp expression
by immunoblot analysis.
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Figure 4-2 Determination of surface expression of P-gp in LS174T cells after
treatment with rifampin and reserpine for 72 hours
Anti-P-gp antibody (MRK-16) and control antibody (γ2) were incubated with solvent
control (DMSO), drug treated cells (rifampin, Rif; reserpine, Res) and blank cells
(without solvent or drug treatment). After washing, the cells were incubated with
fluorescent-labeled secondary antibody. Samples were analyzed for fluorescence
intensity at 530 nm in a flow cytometer.
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Figure 4-3 Uptake of vinblastine in control and rifampin treated cells in the
presence and absence of 5 µM cyclosporin A (CsA)
Bars represent the means ± std.dev (n = 6). Cells were treated with either DMSO (dark
bars) or 10 µM rifampin (hatched bars) for 72 h.
* p<0.05 as compared to vehicle control. Reduction in uptake due to the induction of Pgp by rifampin.
** p<0.05 as compared to vehicle control. Enhanced uptake due to the inhibition of P-gp
by cyclosporin A (+ CsA)
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CYP3A4 activity in LS174T cells after rifampin treatment. Metabolism of
midazolam to 1’-hydroxy midazolam (1’-OH MDZ) was used to measure CYP3A
activity. Formation of 1’-OH MDZ was found to be four times higher in rifampin treated
cells as opposed to control cells (Figure 4.4). Additionally, 1’-OH MDZ formation was
inhibited by 10 µM ketoconazole, a CYP3A inhibitor, Figure 4.4.
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Figure 4-4 Induction of CYP3A activity after 10 µM rifampin treatment.
Formation of 1’-hydroxy midazolam was measured in control and rifampin (Rif) treated
cells after treatment for 72 hrs. The metabolite production was completely inhibited in
presence of 10 µM ketoconazole (Ket) in both the control and rif treated cells.
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Correlation of PXR activation and P-gp induction. A total of 18 compounds,
with known affinity for PXR, were tested for their ability to induce P-gp. Compounds
with high, intermediate and low affinity for PXR were selected and LS174T cells were
treated with 10 µM of drug (except for hyperforin which was tested at 1 µM) in DMSO
for 72 h. P-gp expression was measured by immunoblotting and densitometric values
were determined after scanning the blots. Fold change was calculated with respect to
DMSO control. In Figure 4.5, the fold change in activation of PXR and expression of Pgp is plotted for each of the compounds tested. Of the 18 compounds tested, rifampin,
PNU-721, PNU-444, PNU-690 and SR12813 were strong activators of PXR as well as
greatly induced P-gp expression. Taxol, verapamil and PNU 352 strongly induced P-gp
expression but moderately activated PXR.

On the other hand hyperforin strongly

activated PXR but had very little inducing effect on P-gp expression.

Similarly,

troglitazone was a moderate PXR activator but failed to increase P-gp expression. Lastly
phenytoin and delavirdine resulted in a moderate increase in P-gp expression but failed to
activate PXR. Ibuprofen and dexamethasone did not activate PXR or increase P-gp
expression. The ability of the tested compounds to induce P-gp and activate PXR was
rank ordered and although the rank order differed for P-gp induction and PXR activation,
a positive correlation coefficient of 0.53 (Figure 4.6) was noted which was statistically
significant (p<0.05).
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Figure 4-5 Comparison of PXR Activation and P-gp Induction by Various Agents
LS174T cells were treated with 10 µM of each compound (1 µM hyperforin) for 72 hrs.
At the end of 72 hrs, cells were lysed and P-gp protein abundance was measured by
immunoblotting analysis. Blots were scanned and densitometric values were calculated.
P-gp induction is reported as the fold change over the vehicle control. Likewise, for the
PXR reporter gene assay, data are reported as the fold change over vehicle control.
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Figure 4-6 Correlation between the rank order for PXR Activation and Induction
of P-gp expression

91

4.4. Discussion

The present study demonstrates that LS174T cells can be used as a model cell line
to screen for drugs that can induce P-gp and/or CYP3A. By using a model inducer,
rifampin, we have shown increased expression of P-gp in LS147T cells that was dose
(Figure 4.1) and time dependent.

Schuetz et al. [16] have also shown increased

expression of P-gp and CYP3A4 by immunoblot analysis to be dose dependent in LS180
cells. We were not able to detect CYP3A4 protein by immunoblotting in these cells
before or after treatment with rifampin. However, CYP3A activity was induced in a dose
dependent manner following 72 h of rifampin treatment (data not shown). The inability
to detect protein by immunoblotting was most likely due to the relative insensitivity of
western blotting as compared to activity measurements of formation of 1’-OH MDZ.
CYP3A activity was completely inhibited in the presence of 10 µM ketoconazole, an
inhibitior of CYP3A (Figure 4.4).
Midazolam is a substrate for all CYP3A isoforms (CYP3A4, 5 and 7), however,
the metabolic capabilities differ between the isoforms with CYP3A4 being the most
active or equal to CYP3A5 and CYP3A7 having lower metabolic capacity [102].
CYP3A5 is not induced by rifampin in human hepatocytes, colon carcinoma cell lines
[16] or in human lymphocytes [103]. Moreover, the PXR binding domain is absent in the
5’ promoter region of the CYP3A5 gene [104]. CYP3A7 is mostly found in fetal livers,
however, mRNA for CYP3A7 has been detected in adults [16]. In addition, CYP3A7
was not detected in the LS180 colon carcinoma cell line. Even though the identity of the
induced CYP3A isoform is not known, lines of evidence aforementioned suggest the
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involvement of CYP3A4 primarily. However, further studies are needed to identify the
CYP3A isoform involved.
As MRK-16 anti P-gp antibody recognizes the external epitope of P-gp, it was
used in flow cytometry measurements to determine the surface expression of P-gp in
LS174T cells, as the induced protein needs to be at the cellular surface to be functional.
The fluoresence intensity of vehicle treated cells was compared with that of drug treated
cells. The fluoresence intensity in rifampin treated cells was 3.5 fold higher than vehicle
treated cells, whereas reserpine induced P-gp expression about 4 fold over control cells
(Figure 4.2).
Vinblastine was used as a model substrate to measure P-gp function in LS174T
cells. Cellular accumulation of [3H]-vinblastine was measured in control and rifampin
treated cells (Figure 4.3). The accumulation of [3H]-vinblastine in rifampin treated cells
was significantly less than in control cells as P-gp, an efflux transporter, decreased
intracellular accumulation.

Cyclosporin A (a P-gp inhibitor) treatment significantly

increased [3H]-vinblastine uptake in un-induced cells. Though [3H]-vinblastine uptake
was also increased by CsA in rifampin treated cells, this increase was not statistically
significant. In presence of an inhibitor, the uptake in control and treated cells should be
comparable as the P-gp activity is being blocked / inhibited. It is unclear why the results
were not comparable in our study, but CsA is also a substrate for CYP3A. Since CYP3A
was also induced in this cell line, an increase in CsA metabolism could have resulted in
less CsA available for inhibition of P-gp.
Geick et al. [27] demonstrated that human ABCB1 gene has a PXR response
element in the 5’-upstream region. These investigators reported the presence of PXR
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mRNA in LS174T cells and measured the increased expression of ABCB1 mRNA after
exposing the cells to various PXR activators and CYP3A inducers. Recent studies by
Synold et al. [24] further support the involvement of PXR in induction of ABCB1
transcription. To determine if PXR activators were able to induce the P-gp expression in
LS174T cells, we treated these cells with a total of 18 compounds that had varying
affinities for PXR. A positive correlation was noted with a correlation coefficient of 0.53
(Figure. 4.6) when compounds were rank ordered for PXR activation and induction of Pgp). On excluding outliers like hyperforin, troglitazone and taxol from the analysis, the
correlation coefficient increased to 0.663. Troglitazone and hyperforin showed increased
affinity for PXR but did not increase (troglitazone) or moderately increased (hyperforin)
P-gp expression. The failure of troglitazone and moderate effect of hyperforin to increase
P-gp expression may be explained based on the stability of these compounds. The PXR
reporter gene assay was carried out for 24 hours whereas the LS174T cells were treated
for 72 hours. Because hyperforin and troglitazone are unstable in solution [105;106], this
lag in assay measurement times may explain the lack of effect.
Synold et al. [24] have reported a 50 fold activation of SXR by taxol in a reporter
gene assay. On the other hand Luo et al. [107] have demonstrated a 4 fold activation of
PXR over control after taxol treatment. In our study, taxol activated PXR (2 fold) and
induced P-gp expression (4 fold) over control. The reason(s) for differential effect of
taxol on P-gp expression as compared to PXR activation are unclear. Involvement of
other orphan nuclear receptors apart from PXR or other pathways that could be
responsible for induction of P-gp cannot be excluded.
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In conclusion, our results demonstrate that P-gp and CYP3A proteins were
induced in LS174T cells. This cell line appears to be a good cell based model for
screening compounds for their ability to induce both P-gp and CYP3A proteins. We have
shown that there was a correlation between the ability of compounds to activate PXR and
to increase the expression of P-gp supporting the involvement of PXR in induction of the
ABCB1 gene.
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CHAPTER –V
5. ADDITIONAL RESULTS
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5.1. Sialic acid assay to determine the orientation or sidedness of
membrane vesicles
In the case of inside-out vesicles, the cytoplasmic surface of the membrane forms
the exterior side of the vesicles. The quality of the inside-out vesicles can be determined
by conducting assays to measure the accessibility of markers normally found on the outer
surface of the cells. Sialic acid is one such marker that is typically found on the outer
surface of the cells [80]. In the case of inside-out vesicles, sialic acid will be present on
the interior side of the vesicles and thus not accessible to enzymatic release. Sialidase,
which releases sialic acid from the surface, is not able to penetrate the inside-out vesicles
and thus, only has access to sialic acid located on right side out vesicles and broken
vesicles. Detergents or surfactants can be used to disrupt the vesicles and expose the
sialic acid from inside-out vesicles to sialidase. Thus, experiments were carried out with
and without Triton X-100 (detergent) to determine the percentage of inside-out vesicles.
A standard curve was generated with N-acetyl neuraminic acid (sialic acid) in
concentrations ranging from 20 – 320 µg/ml. The standards and samples were then
derivatized as described in the experimental section (chapter 2) and measured using a UV
spectrophotometer.

The standard curve was validated at low, medium and high

concentrations with 6 replicates of each. The % coefficient of variation (%C.V.) was less
than 20% at all three concentrations. On average, placental vesicle samples were found
to consist of 18 - 20% inside-out vesicles, with the remainder being the right side out or
broken vesicles. Though the percent formation of inside-out vesicles was low, it was
consistent from sample to sample.
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5.2. Alkaline phosphatase assay to determine the enrichment of
vesicles as well as the orientation of membrane vesicles
Alkaline phosphatase is a marker enzyme localized in the microvillus membrane
of cells and can be used to determine the enrichment of microvillus membrane when
isolating membranes from cells or tissue homogenates [79].

Alkaline phosphatase

catalyzes the formation of p-nitrophenol from p-nitrophenylphosphate [83]. The reaction
is performed in alkaline pH as p-nitrophenol is colorless in acidic pH but forms a yellow
color in alkaline pH, due to the p-nitrophenoxide ion. This assay was used to measure the
enrichment of the microvillus membrane in vesicle preparations as well as to determine
the orientation of membrane vesicles.
Alkaline phosphatase activity was determined in various fractions saved from the
process of isolating membrane vesicles from placental tissue. It was observed that the
formation of p-nitrophenol was about 8.5 fold higher in the final microvillus membrane
fraction as compared to the first homogenate. Assuming the alkaline phosphatase activity
in homogenate 1 as 100%, it was noted that supernatant 1 obtained from the
centrifugation of homogenate 1 exhibited 92% of the original alkaline phosphatase
activity, whereas, homogenate 2 exhibited only 8% of the original alkaline phosphatase
activity. These results suggest that most of the microvillus membrane vesicles were
being isolated in first homogenate and there was no need for the second homogenization
step, in agreement with results reported by Illsley et al. [79].
This assay was also used to determine the percentage of inside-out vesicles and
therefore validate the results of the sialic acid assay. The alkaline phosphatase assay was
performed in the presence and absence of detergent and the percentage of inside-out
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vesicles was calculated. Results from this assay were in agreement with the results from
sialic acid assay and showed that the percentage of inside-out membrane vesicles was 1820%.

5.3. Uptake of radiolabeled substrate in membrane vesicles
As the substrates used in the uptake assay were observed to bind non-specifically
to the filters, experiments were carried out to determine the best method for blocking the
non-specific binding of substrate to the filters. Based on literature evidence, 10% fetal
bovine serum, 3% bovine serum albumin and high concentrations of unlabeled
vinblastine were assessed for their ability to block the non-specific binding of vinblastine
to the filters. As seen in Table 5.1, the overall binding to glass fiber filters was less than
to nitrocellulose filters.

In comparing different blocking media, 3% bovine serum

albumin decreased the non-specific binding of radiolabeled vinblastine to less than 10%
of the radioactivity added, irrespective of the type of filter. Based on this experiment,
nitrocellulose filters soaked in 3% bovine serum albumin were used for the uptake
experiments.
To determine the optimum time for incubation of substrate with the vesicles, a
time dependent uptake assay was carried out using vinblastine as the substrate. The
reactions were quenched at different time points in the presence and absence of ATP and
uptake calculated. As vinblastine is highly hydrophobic in nature, a plateau in rate of
uptake was observed within 2 min and which remained constant for 15 min (Figure 5.1).
A convenient time point of 10 min was therefore chosen for further studies.
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To determine if vinblastine uptake was mediated by P-gp without any interference
from ABCP, vinblastine uptake was measured in the presence of P-gp and ABCP
inhibitors. Vinblastine uptake was inhibited by verapamil (10 and 100 µM), a P-gp
inhibitor but not by FTC (10 µM), an ABCP inhibitor, suggesting that vinblastine uptake
was mediated by P-gp and not by ABCP. Similarly mitoxantrone uptake was measured
in the presence of these same inhibitors.

Mitoxantrone uptake was inhibited

approximately 65% by 10 µM FTC but less than 10% by 10 µM verapamil, suggesting
that mitoxantrone uptake is primarily mediated by ABCP. Thus, the P-gp mediated
uptake of vinblastine was not confounded by effects of ABCP and likewise, the ABCP
mediated uptake of mitoxantrone was not affected by concurrent mitoxantrone transport
by P-gp.
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Table 5-1 Non-specific binding of [3H]-vinblastine to nitrocellulose and glass fiber
(GF/F) filters and effect of blocking solutions to reduce the non-specific binding

Treatment
10% FBS

% Radioactivity
Nitrocellulose GF/F filters
42.8
8.3

3% BSA

9.6

5.2

5 µM cold VBL for 1
hour

78.5

35.4

5 µM VBL for 5 min

84.2

43.9

1 µM VBL in quench
buffer

76.5

22.8

10 µM VBL in quench
buffer

25.5

6.6
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Uptake of [3H]-vinblastine
(pmol / mg of protein)

10
8
6
4
with ATP
without ATP
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Time (mins)
Figure 5-1 Time course of [3H]-vinblastine uptake in membrane vesicles
Membrane vesicles were incubated with tritiated vinblastine in transport buffer at 37°C
for various time intervals. The open symbols represent uptake in the presence of 4mM
ATP and the closed symbols in the absence of ATP. Data represent means of duplicate
determinations.
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5.4. Induction studies in BeWo and JAR placental cells
P-gp from human intestinal cells is known to be induced by PXR ligands such as
rifampin [16]. It has also been shown to be induced in human hepatocytes by some Ah
receptor ligands like 3-methylcholanthrene [17]. With this background, we hypothesized
that placental P-gp could also be induced by either PXR or Ah receptor ligands. To
determine the inducibility of placental P-gp, the placental choriocarcinoma cell lines JAR
and BeWo were used as model systems for the human placenta.
After culturing the BeWo cells to 50% confluency, they were treated with
increasing concentrations of rifampin and at the end of 72 h, the cells were lysed.
Similarly, JAR cells were treated with rifampin and clotriamazole (PXR ligands) and 3MC and benzo-[a]-pyrene (Ah receptor ligands) at 50% confluency and at the end of 72
h, the cells were lysed.

The cell lysates were analyzed for P-gp expression by

immunoblotting as described in the experimental section (chapter 2). Little expression of
P-gp was detected in BeWo cells and expression was not induced by rifampin treatment.
In the case of JAR cells, no P-gp expression was detected in either control or treated
cells.
When the JAR cell lysates were probed for ABCP expression, high endogenous
expression of ABCP was noted in control cells but expression did not increase after
treatment with various xenobiotics (Figure 5.2 and 5.3). A polyclonal, ABCP antibody,
anti-MXR 87405 (gift from Dr. Susan Bates, NIH) was used as a primary antibody for
the blot shown in Figure 5.2. Use of this antibody resulted in substantial background
signal and for unknown reasons did not recognize ABCP in human placental samples.
When the BXP-21 antibody from Signet Laboratories was used as a primary antibody for
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ABCP (Figure 5.3), we were able to detect ABCP in both human placental samples as
well as in JAR placental cell lysates. Since BXP-21 gave very little background signal
and also was able to detect ABCP in human placental samples, this primary antibody was
used for immunoblotting studies of ABCP in JAR cells and in human placental samples.
However it was observed that the ABCP protein in human placental samples migrated
differently than the ABCP in the JAR placental cell lysates. These differences could be
due to the differences in post-translational modifications, such as glycosylation. A lower
molecular weight band of ABCP was reported by Litman et al. [73] when a mitoxantrone
selected colon carcinoma cell line which overexpresses ABCP, was treated with
tunicamycin (inhibitor of N-glycosylation) and N-glycosidase F. These results suggest
that ABCP undergoes post-translational modifications at the N-linked glycosylation sites
in this cell line. Whether the ABCP protein in human placenta or the placental cell lines
studied by us undergoes such glycosylation is not known.
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Figure 5-2 Immunoblot of ABCP from JAR placental cell lysates probed with antiMXR antibody 87405
Lane 1 contains the molecular weight markers and lanes 2-7 are JAR cell lysates after
treatment with various xenobiotics. Lane 2: cells with no treatment, 3: acetone, 4:
DMSO, 5: 3-Methylcholanthrene, 6 and 7: 50 µM and 10 µM Benzo-[a]-pyrene,
respectively.
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Figure 5-3 Immunoblot of ABCP from human placental samples and JAR placental
cell lysates probed with BXP-21 primary antibody for ABCP
Lanes 2-9 are human placental vesicle samples and lanes 10 and 11 are JAR cell lysates
after DMSO and 10 µM rifampin treatment, respectively. The ABCP protein in JAR cell
lysates migrated higher than ABCP in human placental vesicles.
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CHAPTER –VI
6. SUMMARY AND CONCLUSIONS
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The placenta is a vital link between mother and fetus and plays an important role
in modulating the passage of xenobiotics from mother to fetus. Generally, it is preferred
that the fetus not be exposed to drugs ingested by the mother during pregnancy; however,
in certain situations such as HIV-infection, fetal transfer of drugs is desired to achieve a
positive therapeutic outcome. Most HIV protease inhibitors are substrates for P-gp and
thus potentially effluxed at the placental level back to the mother, decreasing their
therapeutic efficacy in treating the fetus. P-gp is known to be inducible by xenobiotics
and thus, if placental P-gp induction occurred, a further decrease in the transfer of these
drugs across the placenta would occur. Thus, understanding the inducibility of placental
P-gp is important to be able to predict the therapeutic efficacy of drugs in treating fetal
maladies and for dosage optimization.
The placenta contains enzymes and transporters that can, respectively, metabolize
xenobiotics or cause their efflux back to the mother. Most placental metabolism research
has been focused on the inducibility of placental oxidative enzymes in mothers who
smoke during pregnancy. Cigarette smoke contains polycyclic aromatic hydrocarbons
(PAHs) which are metabolized to carcinogenic compounds by CYP1A1. CYP1A1 is
induced in response to cigarette smoking in human placenta. P-gp, an efflux transporter,
present in the placenta is also known to be induced by PAHs in hepatocytes, however,
whether it is induced in placenta was heretofore unknown. We report here the effect of
smoking on expression and function of P-gp in the human placenta. P-gp function was
measured as the uptake of vinblastine in membrane vesicles prepared from human
placenta.

To assure that vinblastine transport was being measured and not non-

productive binding, a series of initial uptake experiments were carried out in increasing

108

concentrations of sucrose. Results of these experiments demonstrated that transport was
intravesicular. Additional experiments using the P-gp inhibitor verapamil demonstrated
that the observed vinblastine transport was P-gp mediated. Finally, it was noted that
vinblastine transport was comparable between smokers and non-smokers. Similarly no
significant difference was observed in P-gp expression between the two groups.
However, a substantial inter-individual difference was observed that was not attributable
to the effects of smoking. In view of the polymorphisms existing in the ABCB1 gene that
can cause altered expression and function of P-gp, determination of P-gp genotype may
be necessary to provide insight into the substantial inter-individual variation.
The effect of smoking on another efflux transporter, ABCP, was studied in human
placenta. This is the first report of ABCP functional studies in human tissue and its
regulation by smoking. Since ABCP is a half transporter, it is assumed to require
dimerization to become a functional protein. Immunblotting studies for ABCP were
carried out with and without dithiothreitol (DTT), a reducing agent, to determine if
ABCP existed as a dimer in non-reducing conditions. A band was observed at 70 kDa in
reducing conditions and at 140 kDa under non-reducing conditions.

These results

suggest that ABCP exists as a dimer. To further confirm the need for dimerization of
ABCP for functionality, uptake studies in the presence and absence of DTT were carried
out. The ATP dependent uptake of mitoxantrone, an ABCP substrate, was decreased
about 67% in the presence of DTT as compared to the absence of DTT. This confirms
that ABCP requires dimerization to become a functional protein.

When uptake of

mitoxantrone was determined in the presence of ABCP and P-gp inhibitors, it was
observed that mitoxantrone uptake was primarily carried out by ABCP, confirming that
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mitoxantrone was a good substrate for measuring the function of ABCP in vesicles which
also express P-gp. No statistical difference was observed in either function or expression
of ABCP between smokers and non-smokers. Mutations have also been reported in
ABCP overexpressing cell lines, however, whether these mutations exist in humans and
can affect the level of expression and function of ABCP is not known yet. Hence in
addition to P-gp, genotyping studies for ABCP would also be beneficial in understanding
inter-individual differences.
In agreement with literature evidence, placental CYP1A1 activity was induced in
smokers as compared to non-smokers. No correlation in activity was observed between
CYP1A1 and P-gp in human placenta. It has previously been established that the PAH
benzo-[a]-pyrene, a substrate for CYP1A1, is also transported by P-gp. Thus, based on
our observations, it can be implied that the women who smoke during pregnancy and
have high CYP1A1 activity but low P-gp activity, produce more toxic metabolites of
PAH from the cigarette smoke and their fetuses probably have a higher risk of fetal
exposure to these carcinogenic or mutagenic metabolites. We now know that ABCP is
functional in human placenta and probably also plays a protective role by preventing the
placental transfer of xenobiotics. It is not known whether PAHs are substrates for ABCP.
ABCP was not affected by maternal smoking status in this study and the clinical
significance of this finding is not known.
P-gp plays a role in the absorption, distribution and excretion of drugs. It has
broad substrate specificity and due to its efflux nature, leads to the decreased
bioavailability of its substrates. In addition, it is usually co-localized with CYP3A4, an
important drug-metabolizing enzyme. Furthermore, these two proteins have common
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substrates and inducers. Thus, both these proteins can act additively to decrease the
therapeutic efficacy of common substrates and can lead to drug – drug interactions.
Since P-gp and CYP3A4 are both expressed in intestine and have common substrates, we
have evaluated LS174T cells, an intestinal cell line, as a model cell line to screen
compounds for their ability to induce P-gp and CYP3A4 in hopes of better predicting
drug – drug interactions.
Using rifampin as a model inducer, the induction of P-gp and CYP3A4 was
studied in LS174T cells. A dose and time dependent induction of P-gp expression was
noted in these cells. Using flow cytometry and MRK-16, a P-gp antibody that recognizes
an external epitope of P-gp, increased surface expression of P-gp was detected in LS174T
cells after rifampin treatment. This suggests the presence of induced protein at the cell
surface where its presence would be required for efflux of drugs out of the cells.
Decreased vinblastine uptake after rifampin treatment as compared to control cells
indicated induction of the functional activity of P-gp. The studies herein report for the
first time, induction of CYP3A activity in LS174T cells, though increased expression of
CYP3A4 has been reported in LS180 cells. A four fold induction of CYP3A activity,
assessed by formation of 1’ - hydroxymidazolam after rifampin treatment, was noted as
compared to control cells and this activity was inhibited more than 90% by 10 µM
ketoconazole. These results suggest that LS174T cells can be used as a model cell line to
study the induction of P-gp and CYP3A. The isoform of CYP3A induced in these cells,
however, remains to be identified.
In addition, we have also compared and correlated the ability of compounds to
induce P-gp in LS174T cells with their ability to activate PXR in a reporter gene assay.
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The involvement of the nuclear hormone receptor, PXR, in induction of P-gp has been
demonstrated; however, it may not be solely responsible for controlling P-gp expression.
A positive correlation between the ability of compounds to induce P-gp in LS174T cells
and activate PXR was observed, further supporting the role of PXR in P-gp induction.
In addition to being induced by PXR ligands, P-gp is also known to be induced by
some Ah receptor ligands, however, this induction was not reported to proceed via the Ah
receptor pathway. To determine if placental P-gp is inducible by various xenobiotics, the
placental choriocarcinoma cell lines, BeWo and JAR were used to study the induction of
P-gp. Placental cells were treated with the known inducers of P-gp, rifampin and 3methylcholanthrene. P-gp expression was undetectable in JAR cells, in both control and
treated cells, suggesting these compounds did not induce P-gp expression in this placental
cell line. Conversely low P-gp expression was detected in BeWo cells but no induction
was observed after rifampin treatment. Though induction at the protein level was not
detected, it would be useful to perform mRNA studies to determine if induction at the
gene level occurred. Since PXR is known to be expressed in a tissue selective manner,
determination of whether PXR is expressed in human placenta could also provide
valuable insight into our lack of observed induction.
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